US20070282376A1 - Method and apparatus for neural stimulation via the lymphatic system - Google Patents
Method and apparatus for neural stimulation via the lymphatic system Download PDFInfo
- Publication number
- US20070282376A1 US20070282376A1 US11/422,421 US42242106A US2007282376A1 US 20070282376 A1 US20070282376 A1 US 20070282376A1 US 42242106 A US42242106 A US 42242106A US 2007282376 A1 US2007282376 A1 US 2007282376A1
- Authority
- US
- United States
- Prior art keywords
- stimulation
- electrode
- neural
- neural stimulation
- stimulation pulses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(*)C1CCCC1 Chemical compound CC(*)C1CCCC1 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
Definitions
- This document relates generally to medical devices and particularly to an implantable system that delivers neural stimulation via one or more lymphatic vessels.
- Neural stimulation has been applied to treat various pathological conditions. Controlled delivery of electrical stimulation pulses to a nerve generates, modulates, or inhibits activities of that nerve, thereby restoring the functions of that nerve and/or regulating the functions of the tissue or organ innervated by that nerve.
- One specific example of neural stimulation is to regulate cardiac functions and hemodynamic performance by delivering electrical stimulation pulses to portions of the autonomic nervous system.
- the heart is innervated with sympathetic and parasympathetic nerves. Activities in these nerves, including artificially applied electrical stimuli, modulate cardiac functions and hemodynamic performance. Direct electrical stimulation of parasympathetic nerves can activate the baroreflex, inducing a reduction of sympathetic nerve activity and reducing blood pressure by decreasing vascular resistance.
- Sympathetic inhibition as well as parasympathetic activation, has been associated with reduced arrhythmia vulnerability following a myocardial infarction, presumably by increasing collateral perfusion of the acutely ischemic myocardium and decreasing myocardial damage.
- Modulation of the sympathetic and parasympathetic nervous system with neural stimulation has been shown to have positive clinical benefits, such as protecting the myocardium from further remodeling and predisposition to fatal arrhythmias following a myocardial infarction.
- Implantable medical systems are used to deliver neural stimulation.
- a typical implantable neural stimulation system includes an implantable neural stimulator that delivers electrical stimulation pulses through a plurality of stimulation electrodes.
- the stimulation electrodes may be incorporated onto the implantable neural stimulator and/or connected to the implantable neural stimulator using one or more implantable leads.
- the desirable stimulation sites may not be in a location with anatomical structure allowing for easy implantation of the implantable neural stimulator or easy access by the lead(s).
- the degree of risk associated with the implantation procedure increases with the degree of invasiveness. Therefore, given a desirable stimulation site, there is a need to minimize the invasiveness of implanting a system that delivers neural stimulation pulses to that stimulation site.
- An implantable neural stimulation system includes an implantable medical device having a neural stimulation circuit and at least one implantable lead configured to allow one or more stimulation electrodes to be placed in one or more lymphatic vessels of a patient, such as the patient's thoracic duct and/or vessels branching from the thoracic duct.
- Neural stimulation pulses are delivered from the implantable medical device to one or more target regions adjacent to the thoracic duct or the vessels branching from the thoracic duct through the one or more stimulation electrodes.
- a neural stimulation system in one embodiment, includes an electrode assembly and an implantable medical device.
- the electrode assembly includes an electrode base configured to be implanted into a lymphatic vessel and a stimulation electrode on the electrode base.
- the electrode base is configured to cause a portion of the lymphatic vessel to substantially alter its natural path to contact a target region to which neural stimulation pulses are delivered and maintain the contact between the portion of the lymphatic vessel and the target region after the implantation of the electrode assembly.
- the implantable medical device includes a neural stimulation circuit that delivers the neural stimulation pulses through the stimulation electrode.
- a method for delivering neural stimulation is provided.
- Neural stimulation pulses are delivered from an implantable medical device to at least one stimulation electrode placed in a lymphatic vessel.
- FIG. 1 is an illustration of an embodiment of a neural stimulation system and portions of an environment in which the neural stimulation system is used.
- FIG. 2 is an illustration of another embodiment of the neural stimulation system and portions of the environment in which the neural stimulation system is used.
- FIG. 3 is a block diagram illustrating an embodiment of an implantable medical device of the neural stimulation system.
- FIG. 4 is a block diagram illustrating a specific embodiment of the implantable medical device.
- FIG. 5 is a block diagram illustrating another specific embodiment of the implantable medical device.
- FIG. 6 is a block diagram illustrating an embodiment of an external system of the neural stimulation system.
- FIG. 7 is a block diagram illustrating an embodiment of the external system being a patient management system.
- FIG. 8 is a flow chart illustrating a method for delivering neural stimulation via the thoracic duct.
- FIG. 9 is an illustration of a lymphatic vessel and a target region for neural stimulation.
- FIG. 10 is an illustration of an embodiment of an electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation.
- FIG. 11 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation.
- FIG. 12 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation.
- FIG. 13 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation.
- an implantable neural stimulation system including an implantable medical device delivering neural stimulation through at least one stimulation delivery device placed in a lymphatic vessel, such as the thoracic duct, of a patient.
- the implantable neural stimulation system includes a transluminal lead configured for insertion into a portion of the lymphatic vessel to allow one or more stimulation electrodes to be placed in the lymphatic vessel.
- the implantable medical device includes a neural stimulation circuit that generates electrical pulses. The electrical pulses are delivered to one or more target regions adjacent to the lymphatic vessel through the one or more stimulation electrodes placed in the lymphatic vessel.
- neural stimulation pulses are delivered through any one or more lymphatic vessels, including, but not limited to, the thoracic duct, lymphatic vessels branching from the thoracic duct, the right lymphatic duct, and lymphatic vessels branching from the right lymphatic duct.
- the present subject matter includes neurostimulation using any form of energy that is capable of stimulating one or more components of the nervous system via the lymphatic vessel such as the thoracic duct.
- the stimulation delivery device placed in the lymphatic vessel generates or receives neural stimuli, which are then delivered to one or more neural stimulation sites via the lymphatic vessel.
- the neural stimuli are in one or more forms of energy that are capable of eliciting a neural response, such as electrical, magnetic, electromagnetic, thermal, and/or acoustic (including ultrasonic) energy.
- FIG. 1 is an illustration of an embodiment of a neural stimulation system 100 and portions of an environment in which system 100 is used.
- System 100 includes an implantable medical device 110 , a lead 112 , an external system 130 , and a telemetry link 125 providing for communication between implantable medical device 110 and external system 130 .
- System 100 delivers neural stimulation pulses through at least one electrode placed in a thoracic duct 105 , which is part of the lymphatic system of a patient's body 101 .
- the lymphatic system includes lymph tissue, nodes, and vessels. Interstitial fluid is absorbed from tissue, filtered through lymph nodes, and empties into lymphatic vessels.
- FIG. 1 illustrates portions of thoracic duct 105 , a subclavian vein 102 , a left external jugular vein 104 , a left internal jugular vein 103 , and a superior vena cava 106 .
- Thoracic duct 105 connects to the venous system at the juncture of subclavian vein 102 and a left internal jugular vein 103 .
- the fluid (lymph) from the lower body flows up to thoracic duct 105 and empties into subclavian vein 102 from thoracic duct 105 .
- Thoracic duct 105 is located in the posterior mediastinal area of body 101 , adjacent to the heart and various portions of the nervous system including portions of the vagus, sympathetic, and phrenic nerves. Electrical stimulation of such nerves is delivered by using one or more stimulation electrodes placed within thoracic duct 105 .
- Thoracic duct 105 is used as a conduit for advancing the one or more stimulation electrodes to a location from which electrical stimulation can be delivered to a target region of the nervous system of body 101 .
- This approach to the process of electrode placement for neural stimulation has the potential of reducing the invasiveness of implantation procedure under many circumstances.
- Implantable medical device 110 generates neural stimulation pulses that are electrical pulses and delivers the neural stimulation pulses through lead 112 . In one embodiment, implantable medical device 110 also senses neural activities using at least lead 112 . In various embodiments, implantable medical device 110 is capable of sensing other physiological signals and/or delivering therapies in addition to the neural stimulation. Examples of such additional therapies include cardiac pacing therapy, cardioversion/defibrillation therapy, cardiac resynchronization therapy (CRT), cardiac remodeling control therapy (RCT), drug therapy, cell therapy, and gene therapy. In various embodiments, implantable medical device 110 delivers the neural stimulation in coordination with one or more such additional therapies. In one embodiment, in addition to lead 112 , system 100 includes one or more endocardial and/or epicardial leads for delivering pacing and/or defibrillation pulses to the heart.
- Lead 112 is an implantable neural stimulation lead including a proximal end 114 , a distal end 116 , and an elongate lead body 118 between proximal end 114 and distal end 116 .
- Proximal end 114 is coupled to implantable medical device 110 .
- Distal end 116 includes at least one stimulation electrode for delivering the neural stimulation pulses to a target region of the nervous system of body 101 .
- distal end 116 includes stimulation electrodes 120 and 122 .
- distal end 116 includes one stimulation electrode or three or more stimulation electrodes.
- a reference electrode is incorporated onto implantable medical device 110 .
- implantable medical device 110 includes a hermetically sealed conductive housing that functions as the reference electrode.
- Neural stimulation pulses are delivered using (i) two stimulation electrodes in distal end 116 (electrodes 120 or 122 ), or (ii) a stimulation electrode (electrode 120 or 122 ) in distal end 116 and the reference electrode on implantable medical device 110 .
- one or more of the stimulation electrodes are also used for sensing one or more neural signals.
- the distal portion of elongate lead body 118 (a substantial portion of elongate lead body 118 coupled to distal end 116 ) is configured for placement in subclavian vein 102 and thoracic duct 105 , such that distal end 116 is placed in thoracic duct 105 .
- distal end 116 is inserted into subclavian vein 102 through an incision, advanced in subclavian vein 102 toward thoracic duct 105 , inserted into thoracic duct 105 from subclavian vein 102 , and advanced in thoracic duct 105 until a predetermined location in thoracic duct 105 is reached.
- the position of distal end 116 is adjusted by delivering test neural stimulation pulses and detecting evoked neural signals and/or other physiological responses.
- lead 112 includes a fixation mechanism configured to stabilize distal end 116 in the determined position in thoracic duct 105 .
- Implantable medical device 110 is connected to proximal end 114 and is subcutaneously implanted.
- One example of method and apparatus for accessing the lymphatic system is discussed in U.S. patent application Ser. No., ______, entitled “METHOD AND APPARATUS FOR LYMPHATIC SYSTEM PACING AND SENSING,” filed on even date herewith (Attorney Docket No. 279.A69 ⁇ l), assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety. Specific examples of electrode configurations and placement are also discussed in detail below, with reference to FIGS. 9-12 .
- lead 112 is configured such that distal end 116 can be further advanced into a lymphatic vessel branching from thoracic duct 105 , such as the gastric branch, so that the stimulation electrode can be placed in close proximity of a desirable target region.
- the distal end 116 is inserted into thoracic duct 105 , it is advanced to the junction of thoracic duct 105 and the branching lymphatic vessel and inserted to the branching lymphatic vessel.
- the present subject matter generally includes introducing one or more stimulus delivery devices such as one or more stimulation electrodes to a stimulation site via a lymphatic vessel.
- neural stimulation pulses are delivered through one or more stimulation electrodes placed in the lymphatic vessel and/or one or more stimulation electrodes placed in a structure that is accessible through the lymphatic vessel, including another lymphatic vessel branching from the lymphatic vessel.
- system 100 includes two or more leads each including one or more stimulation electrodes arranged to be placed in thoracic duct 105 .
- a lead includes a plurality of electrodes arranged for delivering independently controllable neural stimulation pulses to two or more target regions.
- External system 130 communicates with implantable medical device 110 and provides for access to implantable medical device 110 by a physician or other caregiver.
- external system 130 includes a programmer.
- external system 130 is a patient management system including an external device communicating with implantable medical device 110 via telemetry link 125 , a remote device in a relatively distant location, and a telecommunication network linking the external device and the remote device.
- the patient management system allows access to implantable medical device 110 from a remote location, for purposes such as monitoring patient status and adjusting therapies.
- telemetry link 125 is an inductive telemetry link.
- telemetry link 125 is a far-field radio-frequency (RF) telemetry link.
- RF radio-frequency
- Telemetry link 125 provides for data transmission from implantable medical device 110 to external system 130 . This includes, for example, transmitting real-time physiological data acquired by implantable medical device 110 , extracting physiological data acquired by and stored in implantable medical device 110 , extracting patient history data such as occurrences of predetermined types of pathological events and therapy deliveries recorded in implantable medical device 110 , and/or extracting data indicating an operational status of implantable medical device 110 (e.g., battery status and lead impedance). Telemetry link 125 also provides for data transmission from external system 130 to implantable medical device 110 .
- Telemetry link 125 also provides for data transmission from external system 130 to implantable medical device 110 .
- programming implantable medical device 110 to acquire physiological data programming implantable medical device 110 to perform at least one self-diagnostic test (such as for a device operational status), and/or programming implantable medical device 110 to deliver one or more therapies and/or to adjust the delivery of one or more therapies.
- FIG. 2 is an illustration of an embodiment of a neural stimulation system 200 and portions of the environment in which system 200 is used.
- System 200 includes the components of neural stimulation system 100 and an additional lead. That is, neural stimulation system 200 includes implantable medical device 110 , leads 112 and 232 , external system 130 , and telemetry link 125 .
- Lead 232 is an implantable neural stimulation lead including a proximal end 234 , a distal end 236 , and an elongate lead body 238 between proximal end 234 and distal end 236 .
- Proximal end 234 is coupled to implantable medical device 110 .
- Distal end 236 includes at least one electrode.
- lead 232 includes an electrode 240 at distal end 236 .
- lead 232 includes a plurality of stimulation electrodes.
- lead 232 is configured for subcutaneous placement, external to thoracic duct 105 .
- electrode 240 is used as a reference electrode.
- Lead 232 expands the range of target regions to which neural stimulation pulses can be delivered from implantable medical device 110 .
- neural stimulation pulses are delivered through any pair of electrodes of system 200 including (i) two stimulation electrodes in distal end 116 (electrodes 120 and 122 ), (ii) a stimulation electrode in distal end 116 (electrode 120 or 122 ) and electrode 240 (as the reference electrode), or (iii) a stimulation electrode in distal end 116 (electrode 120 or 122 ) and the reference electrode on implantable medical device 110 .
- distal ends 116 and 236 are positioned such as a target structure for the neural stimulation is approximately between a stimulation electrode in distal end 116 (electrode 120 or 122 ) and a reference electrode (electrode 240 or the reference electrode on implantable medical device 110 ).
- the target structure is a portion of the spinal cord of body 101 .
- FIG. 3 is a block diagram illustrating an embodiment of an implantable medical device 310 , which is a specific embodiment of implantable medical device 110 .
- Implantable medical device 310 includes a neural stimulation circuit 346 and an implant control circuit 348 .
- Neural stimulation circuit 346 delivers neural stimulation pulses to a pair of stimulation electrodes 342 and 344 , through which the neural stimulation pulses are delivered to a target region in the nervous system. At least one of stimulation electrodes 342 and 344 is placed in thoracic duct 105 .
- Implant control circuit 348 controls the delivery of the neural stimulation pulses from neural stimulation circuit 346 .
- stimulation electrodes 342 and 344 are both in thoracic duct 105 and adjacent to the target region, such as electrodes 120 and 122 .
- stimulation electrode 342 is in thoracic duct 105 and adjacent to the target region, such as electrode 120 or 122
- stimulation electrode 344 is external to thoracic duct 105 , such as electrode 240 or a reference electrode on implantable medical device 310 .
- the target region is approximately between stimulation electrodes 342 and 344 .
- the target region includes one or more components of the nervous system that are adjacent to the thoracic duct in the posterior mediastinal region or abdominal region.
- the target region include the sympathetic nerves, the parasympathetic nerves (including the vagus nerve), the phrenic nerve, the spinal cord, the brain stem, the renal nerves, and the baroreceptors in the carotid artery and aorta.
- cardiac functions are regulated by applying neural stimulation including one or more of sympathetic excitation, sympathetic inhibition, parasympathetic excitation, and parasympathetic inhibition.
- One example of a system capable of providing excitatory stimulation and inhibitory stimulation to both sympathetic nerves and parasympathetic nerves is discussed in U.S.
- FIG. 3 shows the pair of stimulation electrodes 342 and 344 .
- neural stimulation circuit 346 delivers neural stimulation pulses through one or more pairs of stimulation electrodes selected from a plurality of stimulation electrodes.
- neural stimulation circuit 346 includes two or more stimulation output channels each delivering neural stimulation pulses through a pair of stimulation electrodes.
- an electrode array with a plurality of stimulation electrodes is placed in the thoracic duct, and one or more stimulation electrodes are selected for delivering neural stimulation pulses by testing the physiological effect of stimulation associated with each stimulation electrode.
- FIG. 4 is a block diagram illustrating an embodiment of an implantable medical device 410 , which is another specific embodiment of implantable medical device 110 .
- Implantable medical device 410 includes neural stimulation circuit 346 , a sensing circuit 452 , an implant control circuit 448 , and an implant telemetry circuit 458 .
- One or more physiological sensors 450 are housed within implantable medical device 410 , incorporated onto implantable medical device 410 , and/or connected to implantable medical device 410 using a lead.
- Physiological sensor(s) 450 sense one or more physiological signals indicative of neural function and/or physiological functions regulated by the components of the nervous system to be stimulated. Sensing circuit 452 processes the one or more physiological signals and produces signals indicative of a need to start, stop, or adjust the neural stimulation. Examples of such physiological signals include signals indicative of heart rate, heart rate variability (HRV), and blood pressure.
- physiological sensor(s) 450 include one or both of stimulation electrodes 342 and 344 , which are utilized as sensing electrodes.
- Implant control circuit 448 is a specific embodiment of implant control circuit 348 and controls the delivery of the neural stimulation pulses from neural stimulation circuit 346 using a plurality of stimulation parameters.
- Implant control circuit 448 includes a parameter storage circuit 454 and a parameter receiver 456 .
- Parameter storage circuit 454 stores values of the plurality of stimulation parameters. Examples of such stimulation parameters include pulse amplitude, pulse width, and pulse frequency (or inter-pulse interval). The values of the plurality of stimulation parameters are adjustable.
- Parameter receiver 456 receives values of the plurality of stimulation parameters and updates parameter storage circuit 454 with the received values.
- implant control circuit 448 controls the delivery of the neural stimulation pulses from neural stimulation circuit 346 using one or more physiological signals sensed by physiological sensor(s) 450 .
- each sensed physiological signal is used as one or more of a triggering signal to start or stop the neural stimulation, a safety assurance signal to start, stop, or adjust the intensity of the neural stimulation, and a feedback signal to provide closed-loop neural stimulation.
- Implant telemetry circuit 458 transmits and receives data via telemetry link 125 .
- the values of the plurality of stimulation parameters are externally programmable, and the programmed values are received from external system 130 through telemetry link 125 .
- FIG. 5 is a block diagram illustrating an implantable medical device 510 , which is a specific embodiment of implantable medical device 410 .
- Implantable medical device 510 includes neural stimulation circuit 346 , a neural sensing circuit 552 , an implant control circuit 548 , and implant telemetry circuit 458 .
- Neural sensing circuit 552 is a specific embodiment of sensing circuit 452 and processes a neural signal sensed using neural sensing electrodes 562 and 564 , which represent a specific embodiment of physiological sensor(s) 450 .
- neural sensing circuit 552 processes two or more neural signals sensed using additional neural sensing electrodes.
- the neural signal is sensed from the same site to which the neural stimulation pulses are delivered, and stimulation electrodes 342 and 344 are used as neural sensing electrodes 562 and 564 .
- stimulation electrodes 342 and 344 and neural sensing electrodes 562 and 564 are physically the same pair of electrodes.
- the neural signal is sensed from a site different from the site to which the neural stimulation pulses are delivered. At least one of stimulation electrodes 342 and 344 is not used as any of neural sensing electrodes 562 and 564 .
- Implant control circuit 548 is a specific embodiment of implant control circuit 448 and includes a closed-loop controller 560 , parameter storage circuit 454 , and parameter receiver 456 .
- Implant control circuit 548 controls the delivery of the neural stimulation pulses from neural stimulation circuit 346 using a plurality of stimulation parameters and the sensed and processed neural signal.
- Closed-loop controller 560 controls the delivery of the neural stimulation pulses using the sensed and processed neural signal as an input for feedback control. Examples of closed-loop neural stimulation are discussed in U.S. patent application Ser. No. 11/280,940, entitled “SYSTEM AND METHOD FOR CLOSED-LOOP NEURAL STIMULATION,” filed on Nov. 16, 2005, assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety.
- FIG. 6 is a block diagram illustrating an embodiment of an external system 630 , which is a specific embodiment of external system 130 .
- External system 630 includes an external telemetry circuit 670 , an external controller 672 , and a user interface 674 .
- External telemetry circuit 670 transmits and receives data via telemetry link 125 .
- External controller 672 controls the operation of external system 630 .
- User interface 674 allows a user such as a physician or other caregiver to communicate with implantable medical device 110 through external system 630 .
- User interface 674 includes a presentation device 676 and a user input device 678 .
- User input device 678 allows for the programming of the values of the plurality of stimulation parameters.
- presentation device 676 and user input device 678 are integrated or partially integrated to include an interactive screen allowing for programming of implantable medical device 110 .
- external system 630 includes a programmer. In another embodiment, external system 630 includes a patient management system as discussed below with reference to FIG. 7 .
- FIG. 7 a block diagram illustrating an embodiment of an external system 730 , which is a specific embodiment of external system 630 .
- external system 730 is a patient management system including an external device 780 , a telecommunication network 782 , and a remote device 784 .
- External device 780 is placed within the vicinity of implantable medical device 110 and includes external telemetry system 670 to communicate with the implantable medical device via telemetry link 125 .
- Remote device 784 is in a remote location and communicates with external device 780 through network 782 .
- Remote device 784 includes user interface 674 to allow the physician or other caregiver to monitor and treat a patient from a distant location and/or allowing access to various treatment resources from the remote location.
- FIG. 8 is a flow chart illustrating a method for delivering neural stimulation via the thoracic duct. In one embodiment, the method is performed using system 100 or system 200 , including the various embodiments of their components discussed above.
- a neural stimulation lead is inserted into a lymphatic vessel of a patient at 800 .
- this lymphatic vessel is the thoracic duct.
- the neural stimulation lead is an implantable transluminal lead having a proximal end configured for connection to an implantable medical device and a distal end including one or more stimulation electrodes.
- an opening is made on the subclavian vein, upstream from the junction of the subclavian vein and the ostium of the thoracic duct.
- the distal end of the neural stimulation lead is inserted into the subclavian vein through the opening and advanced toward the junction of the subclavian vein and the ostium of the thoracic duct downstream. Then, the neural stimulation lead is guided into the thoracic duct and advanced in the thoracic duct until the distal end reaches a region determined by the target to which the neural stimulation pulses are delivered.
- the target region examples include any nerve of other components of the nervous system in the mediastinal or abdominal region, adjacent to the thoracic duct, such as sympathetic nerves, parasympathetic nerves including the vagus nerve, the phrenic nerve, renal nerves, the spinal cord, the brain stem, and baroreceptors in the carotid artery and aorta.
- the distal end of the neural stimulation lead is guided into a lymphatic vessel branching from the thoracic duct.
- the stimulation electrode(s) of the neural stimulation lead are positioned in the lymphatic vessel, such as the thoracic duct or the lymphatic vessel branching from the thoracic duct, at 810 .
- test neural stimulation pulses are delivered.
- the distal end is moved in the thoracic duct or the lymphatic vessel branching from the thoracic duct until it reaches a position identified by detecting satisfactory responses to the stimulation, such as evoked neural signals and/or other anticipated physiological effects.
- the distal end with the stimulation electrode(s) is then stabilized in that position.
- the neural stimulation lead includes a plurality of stimulation electrodes.
- test neural stimulation pulses are delivered to different stimulation electrodes or different combinations of the stimulation electrodes, one at a time.
- a stimulation electrode or a combination of stimulation electrodes is identified for an intended therapy based on the responses to the stimulation, such as evoked neural signals and/or other anticipated physiological effects.
- One or more physiological signals are sensed at 820 .
- at least one physiological signal is sensed to indicate a need to start, stop, or adjust the delivery of the neural stimulation.
- at least one physiological signal is sensed for monitoring, diagnostic, and/or therapeutic purposes other then the neural stimulation.
- one or more neural signals are sensed.
- a neural signal is sensed from the nerve to which the neural stimulation is delivered.
- one or more signals each indicative of a physiological function regulated by the stimulated nerve are sensed.
- Neural stimulation pulses are delivered using the stimulation electrode(s) positioned in the lymphatic vessel, such as the thoracic duct or the lymphatic vessel branching from the thoracic duct, at 830 .
- the neural stimulation pulses are delivered through two stimulation electrodes positioned in the thoracic duct or the lymphatic vessel branching from the thoracic duct.
- the neural stimulation pulses are delivered using a stimulation electrode positioned in the thoracic duct or the lymphatic vessel branching from the thoracic duct and another stimulation electrode positioned in a location in the body external to the lymphatic vessels.
- the neural stimulation pulses are delivered to a portion of the nervous system approximately between a pair of stimulation electrodes.
- the delivery of the neural stimulation pulses is controlled using a plurality of stimulation parameters.
- the stimulation parameters include pulse amplitude, pulse width, and pulse frequency (or inter-pulse interval). These stimulation parameters are adjustable.
- a user such as a physician or other caregiver programs one or more values of the plurality of stimulation parameters.
- the delivery of the neural stimulation pulses are also controlled using the one or more physiological signals, including the one or more neural signals.
- the neural stimulation pulses are delivered via the thoracic duct or the lymphatic vessel branching from the thoracic duct to treat one or more clinical conditions each associated with a physiological function regulated by a nerve or other component of the nervous system that is adjacent the thoracic duct or the lymphatic vessel branching from the thoracic duct.
- clinical conditions include respiratory disorders, abnormal blood pressure, cardiac arrhythmias, myocardial infarction or ischemic insult (angina), heart failure, epilepsy, depression, renal disorders, pain, migraine, obesity, movement disorders, and incontinence.
- the treatment include (i) treatment of hypertension by baroreceptor stimulation, (ii) treatment of heart failure by sympathetic inhibition or vagal excitation; (iii) control of post-myocardial infarction remodeling by sympathetic inhibition or vagal excitation, (iv) mitigation of chronic pain by neural activation or blocking, (v) treatment of vascular pain including refractory angina and peripheral vascular diseases (PVD) by spinal cord stimulation, (vi) treatment of rachidian pain including failed back surgery syndrome (FBSS), degenerative low back leg pain (LBLP), nerve root lesions, incomplete spine lesions and spinal stenosis by spinal cord stimulation, (vii) treatment of type 1 or type 2 chronic regional pain syndrome (CRPS) by spinal cord stimulation, and (viii) treatment of perineal pain and urological diseases by spinal cord stimulation, and restoration of lower extremity motor functions such as standing and walking after spinal cord injury by ventral spinal cord stimulation.
- vascular pain including refractory angina and peripheral vascular diseases (PVD) by spinal cord stimulation
- PVD
- FIGS. 9-13 illustrate, by way of example, various embodiments of an electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation.
- the electrode assembly includes one or more electrode bases.
- One or more stimulation electrodes are incorporated onto and/or integrated with each of the one or more electrode bases.
- the one or more electrode bases each are formed as portion of a lead such as lead 112 .
- an electrode base is formed at distal end 116 of lead 112 , and stimulation electrodes 120 and 122 are on that electrode base.
- one or more electrode bases are formed in elongate lead body 118 of lead 112 .
- electrode bases are formed at distal end 116 and elongate lead body 118 of lead 112 to provide for delivery of the neural stimulation pulses to multiple target regions.
- FIG. 9 is an illustration of a lymphatic vessel 905 and a target region 907 in their natural state.
- Target region 907 is a region in the nervous system to which the neural stimulation pulses are delivered.
- lymphatic vessel 905 and target region 907 are not in direct contact, or not constantly in direct contact, with each other in their natural state.
- Electrode assemblies illustrated in FIGS. 10-13 each cause and maintain a substantially constant and direct contact between lymphatic vessel 905 and target region 907 by substantially altering the natural path of lymphatic vessel 905 .
- Such a substantially constant and direct contact allows for a reliable delivery of neural stimulation pulses from one or more electrodes in lymphatic vessel 905 to target region 907 .
- lymphatic vessel 905 represents one of the thoracic duct, a vessel branching from the thoracic duct, or any lymphatic vessel suitable for placement of the one or more electrodes for the delivery of the neural stimulation pulses.
- FIG. 10 is an illustration of an embodiment of an electrode assembly including an electrode base 1021 configured to be implanted in lymphatic vessel 905 and a stimulation electrode 1020 on electrode base 1021 .
- Electrode base 1021 has an elongate shape and includes a bias configured to cause a portion of lymphatic vessel 905 to substantially alter its natural path to contact target region 907 . The bias also allows electrode 1020 to be in contact with the inner wall of lymphatic vessel 905 for delivering the neural stimulation pulses to target region 907 .
- Electrode base 1021 has a stiffness allowing for stabilizing the position of stimulation electrode 1020 in lymphatic vessel 905 and maintaining the contact between the portion of lymphatic vessel 905 and target region 907 after implantation.
- electrode base 1021 is in a helical form.
- electrode base 1021 includes an elongate body having shape memory characteristics such that it returns to its preformed shape after the implantation procedure during which a stylet or guide wire may be used.
- the shape memory characteristics are provided by using a shape memory polymer such as polyether polyurethane or a shape memory metal.
- the electrode assembly is coupled to implantable medical device 110 via a lead such as lead 112 .
- electrode base 1021 is formed at distal end 116 of lead 112 , with stimulation electrode 1020 being stimulation electrode 120 . In other specific embodiments, two or more stimulation electrodes are incorporated into electrode base 1021 .
- FIG. 11 is an illustration of an embodiment of another electrode assembly including an electrode base 1121 configured to be implanted in lymphatic vessel 905 and stimulation electrodes 1120 and 1122 , both on electrode base 1121 .
- Electrode base 1121 has an elongate shape and includes a bias configured to cause a portion of lymphatic vessel 905 to substantially alter its natural path to contact target region 907 .
- the bias also allows electrodes 1120 and 1122 to be in contact with the inner wall of lymphatic vessel 905 for delivering the neural stimulation pulses to target region 907 using either or both of electrodes 1120 and 1122 .
- Electrode base 1121 has the stiffness allowing for stabilizing the positions of stimulation electrodes 1120 and 1122 in lymphatic vessel 905 and maintaining the contact between the portion of lymphatic vessel 905 and target region 907 after implantation.
- electrode base 1121 is in a helical form.
- electrode base 1121 includes an elongate body having shape memory characteristics such that it returns to its preformed shape after the implantation procedure during which a stylet or guide wire may be used. The shape memory characteristics are provided by using a shape memory polymer such as polyether polyurethane or a shape memory metal.
- the electrode assembly is coupled to implantable medical device 110 via a lead such as lead 112 .
- electrode base 1121 is formed at distal end 116 of lead 112 , with stimulation electrodes 1120 and 1122 being stimulation electrodes 120 and 122 . In other specific embodiments, one stimulation electrode, or three or more stimulation electrodes, are incorporated into electrode base 1121 .
- FIG. 12 is an illustration of an embodiment of another electrode assembly including an electrode base 1121 with stimulation electrodes 1120 and 1122 and another electrode base 1221 with stimulation electrodes 1220 and 1222 .
- Electrode bases 1121 and 1221 are both configured to be implanted in lymphatic vessel 905 .
- Electrode bases 1121 has the elongate shape and includes the bias configured to cause a portion of lymphatic vessel 905 to substantially alter its natural path to contact target region 907 .
- the bias also allows electrodes 1120 and 1122 to be in contact with the inner wall of lymphatic vessel 905 for delivering neural stimulation pulses to target region 907 using either or both of electrodes 1120 and 1122 .
- Electrode bases 1221 has an elongate shape and includes a bias configured to cause a portion of lymphatic vessel 905 to substantially alter its natural path to contact a target region 1207 .
- the bias also allows electrodes 1220 and 1222 to be in contact with the inner wall of lymphatic vessel 905 for delivering neural stimulation pulses to target region 1207 using either or both of electrodes 1220 and 1222 .
- Electrode bases 1121 and 1221 each have a stiffness allowing for stabilizing the positions of the stimulation electrodes in lymphatic vessel 905 and maintaining the contact between the portion of lymphatic vessel 905 and target region 907 after implantation.
- electrode bases 1121 and 1221 are each in a helical form.
- electrode bases 1121 and 1221 each include an elongate body having shape memory characteristics such that it returns to its preformed shape after the implantation procedure during which a stylet or guide wire may be used.
- the shape memory characteristics are provided by using a shape memory polymer such as polyether polyurethane or a shape memory metal.
- the electrode assembly is coupled to implantable medical device 110 via a lead such as lead 112 .
- electrode base 1121 is formed at distal end 116 of lead 112 , with stimulation electrodes 1120 and 1122 being stimulation electrodes 120 and 122 , and electrode base 1221 is formed in elongate lead body 118 of lead 112 .
- one stimulation electrode, or three or more stimulation electrodes are incorporated into each of electrode bases 1121 and 1221 .
- FIG. 13 is an illustration of an embodiment of another electrode assembly including an electrode base 1321 and a stimulation electrode 1320 .
- Electrode base 1321 is expandable. After being expanded, electrode base 1321 causes a portion of lymphatic vessel 905 to substantially expand to contact target region 907 . The expansion of electrode base 1321 also allows electrode 1320 to be in stable contact with the inner wall of lymphatic vessel 905 for delivering neural stimulation pulses to target region 907 .
- electrode base 1321 includes a stent that is expanded in the lymphatic vessel to maintain patency of the vessel.
- stimulation electrode 1320 is incorporated into the stent.
- the stent is made of metal and functions as stimulation electrode 1320 .
- stimulation electrode 1320 is integrated into the stent to be a portion of its structure.
- the stent also stabilize the position of stimulation electrode 1320 in lymphatic vessel 905 and prevents obstruction of the lymphatic flow.
- the electrode assembly is coupled to implantable medical device 110 via a lead such as lead 112 .
- the stent is incorporated into distal end 116 of lead 112 .
- the stent is incorporated into elongate lead body 118 of lead 112 .
- two or more stents are incorporated into elongate lead body 118 and/or distal end 116 of lead 112 .
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
An implantable neural stimulation system includes an implantable medical device having a neural stimulation circuit and at least one implantable lead configured to allow one or more stimulation electrodes to be placed in one or more lymphatic vessels of a patient, such as the patient's thoracic duct and/or vessels branching from the thoracic duct. Neural stimulation pulses are delivered from the implantable medical device to one or more target regions adjacent to the thoracic duct or the vessels branching from the thoracic duct through the one or more stimulation electrodes.
Description
- This application is related to co-pending, commonly assigned, U.S. patent application Ser. No. ______, entitled “METHOD AND APPARATUS FOR LYMPHATIC SYSTEM PACING AND SENSING,” filed on even date herewith (Attorney Docket No. 279.A69US1), U.S. patent application Ser. No. ______, entitled “METHOD AND APPARATUS FOR GASTROINTESTINAL STIMULATION VIA THE LYMPHATIC SYSTEM,” filed on even date herewith ______ (Attorney Docket No. 279.A66US1), U.S. patent application Ser. No. ______, entitled “METHOD AND DEVICE FOR LYMPHATIC SYSTEM MONITORING,” filed even date herewith (Attorney Docket No. 279.A05US1), and U.S. patent application Ser. No. ______, entitled “METHOD AND DEVICE FOR ENDO-LYMPHATIC STIMULATION,” filed on even date herewith (Attorney Docket No. 279.A04US1), which are hereby incorporated herein by reference in their entirety.
- This document relates generally to medical devices and particularly to an implantable system that delivers neural stimulation via one or more lymphatic vessels.
- Neural stimulation has been applied to treat various pathological conditions. Controlled delivery of electrical stimulation pulses to a nerve generates, modulates, or inhibits activities of that nerve, thereby restoring the functions of that nerve and/or regulating the functions of the tissue or organ innervated by that nerve. One specific example of neural stimulation is to regulate cardiac functions and hemodynamic performance by delivering electrical stimulation pulses to portions of the autonomic nervous system. The heart is innervated with sympathetic and parasympathetic nerves. Activities in these nerves, including artificially applied electrical stimuli, modulate cardiac functions and hemodynamic performance. Direct electrical stimulation of parasympathetic nerves can activate the baroreflex, inducing a reduction of sympathetic nerve activity and reducing blood pressure by decreasing vascular resistance. Sympathetic inhibition, as well as parasympathetic activation, has been associated with reduced arrhythmia vulnerability following a myocardial infarction, presumably by increasing collateral perfusion of the acutely ischemic myocardium and decreasing myocardial damage. Modulation of the sympathetic and parasympathetic nervous system with neural stimulation has been shown to have positive clinical benefits, such as protecting the myocardium from further remodeling and predisposition to fatal arrhythmias following a myocardial infarction.
- Implantable medical systems are used to deliver neural stimulation. A typical implantable neural stimulation system includes an implantable neural stimulator that delivers electrical stimulation pulses through a plurality of stimulation electrodes. Depending on the location of the nerve to be stimulated, the stimulation electrodes may be incorporated onto the implantable neural stimulator and/or connected to the implantable neural stimulator using one or more implantable leads. In practice, the desirable stimulation sites may not be in a location with anatomical structure allowing for easy implantation of the implantable neural stimulator or easy access by the lead(s). The degree of risk associated with the implantation procedure increases with the degree of invasiveness. Therefore, given a desirable stimulation site, there is a need to minimize the invasiveness of implanting a system that delivers neural stimulation pulses to that stimulation site.
- An implantable neural stimulation system includes an implantable medical device having a neural stimulation circuit and at least one implantable lead configured to allow one or more stimulation electrodes to be placed in one or more lymphatic vessels of a patient, such as the patient's thoracic duct and/or vessels branching from the thoracic duct. Neural stimulation pulses are delivered from the implantable medical device to one or more target regions adjacent to the thoracic duct or the vessels branching from the thoracic duct through the one or more stimulation electrodes.
- In one embodiment, a neural stimulation system includes an electrode assembly and an implantable medical device. The electrode assembly includes an electrode base configured to be implanted into a lymphatic vessel and a stimulation electrode on the electrode base. The electrode base is configured to cause a portion of the lymphatic vessel to substantially alter its natural path to contact a target region to which neural stimulation pulses are delivered and maintain the contact between the portion of the lymphatic vessel and the target region after the implantation of the electrode assembly. The implantable medical device includes a neural stimulation circuit that delivers the neural stimulation pulses through the stimulation electrode.
- In one embodiment, a method for delivering neural stimulation is provided. Neural stimulation pulses are delivered from an implantable medical device to at least one stimulation electrode placed in a lymphatic vessel.
- This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects of the invention will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof. The scope of the present invention is defined by the appended claims and their legal equivalents.
- The drawings illustrate generally, by way of example, various embodiments discussed in the present document. The drawings are for illustrative purposes only and may not be to scale.
-
FIG. 1 is an illustration of an embodiment of a neural stimulation system and portions of an environment in which the neural stimulation system is used. -
FIG. 2 is an illustration of another embodiment of the neural stimulation system and portions of the environment in which the neural stimulation system is used. -
FIG. 3 is a block diagram illustrating an embodiment of an implantable medical device of the neural stimulation system. -
FIG. 4 is a block diagram illustrating a specific embodiment of the implantable medical device. -
FIG. 5 is a block diagram illustrating another specific embodiment of the implantable medical device. -
FIG. 6 is a block diagram illustrating an embodiment of an external system of the neural stimulation system. -
FIG. 7 is a block diagram illustrating an embodiment of the external system being a patient management system. -
FIG. 8 is a flow chart illustrating a method for delivering neural stimulation via the thoracic duct. -
FIG. 9 is an illustration of a lymphatic vessel and a target region for neural stimulation. -
FIG. 10 is an illustration of an embodiment of an electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation. -
FIG. 11 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation. -
FIG. 12 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation. -
FIG. 13 is an illustration of an embodiment of another electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation. - In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their legal equivalents.
- This document discusses an implantable neural stimulation system including an implantable medical device delivering neural stimulation through at least one stimulation delivery device placed in a lymphatic vessel, such as the thoracic duct, of a patient. In one embodiment, the implantable neural stimulation system includes a transluminal lead configured for insertion into a portion of the lymphatic vessel to allow one or more stimulation electrodes to be placed in the lymphatic vessel. The implantable medical device includes a neural stimulation circuit that generates electrical pulses. The electrical pulses are delivered to one or more target regions adjacent to the lymphatic vessel through the one or more stimulation electrodes placed in the lymphatic vessel. While the thoracic duct is specifically discussed in this document as an example of such a lymphatic vessel, neural stimulation pulses are delivered through any one or more lymphatic vessels, including, but not limited to, the thoracic duct, lymphatic vessels branching from the thoracic duct, the right lymphatic duct, and lymphatic vessels branching from the right lymphatic duct.
- While electrical stimulation is specifically discussed in this document as an example, the present subject matter includes neurostimulation using any form of energy that is capable of stimulating one or more components of the nervous system via the lymphatic vessel such as the thoracic duct. In various embodiments, the stimulation delivery device placed in the lymphatic vessel generates or receives neural stimuli, which are then delivered to one or more neural stimulation sites via the lymphatic vessel. The neural stimuli are in one or more forms of energy that are capable of eliciting a neural response, such as electrical, magnetic, electromagnetic, thermal, and/or acoustic (including ultrasonic) energy.
-
FIG. 1 is an illustration of an embodiment of aneural stimulation system 100 and portions of an environment in whichsystem 100 is used.System 100 includes an implantablemedical device 110, alead 112, anexternal system 130, and atelemetry link 125 providing for communication between implantablemedical device 110 andexternal system 130. -
System 100 delivers neural stimulation pulses through at least one electrode placed in athoracic duct 105, which is part of the lymphatic system of a patient'sbody 101. The lymphatic system includes lymph tissue, nodes, and vessels. Interstitial fluid is absorbed from tissue, filtered through lymph nodes, and empties into lymphatic vessels.FIG. 1 illustrates portions ofthoracic duct 105, asubclavian vein 102, a left externaljugular vein 104, a left internaljugular vein 103, and asuperior vena cava 106.Thoracic duct 105 connects to the venous system at the juncture ofsubclavian vein 102 and a left internaljugular vein 103. The fluid (lymph) from the lower body flows up tothoracic duct 105 and empties intosubclavian vein 102 fromthoracic duct 105.Thoracic duct 105 is located in the posterior mediastinal area ofbody 101, adjacent to the heart and various portions of the nervous system including portions of the vagus, sympathetic, and phrenic nerves. Electrical stimulation of such nerves is delivered by using one or more stimulation electrodes placed withinthoracic duct 105.Thoracic duct 105 is used as a conduit for advancing the one or more stimulation electrodes to a location from which electrical stimulation can be delivered to a target region of the nervous system ofbody 101. This approach to the process of electrode placement for neural stimulation has the potential of reducing the invasiveness of implantation procedure under many circumstances. - Implantable
medical device 110 generates neural stimulation pulses that are electrical pulses and delivers the neural stimulation pulses throughlead 112. In one embodiment, implantablemedical device 110 also senses neural activities using at least lead 112. In various embodiments, implantablemedical device 110 is capable of sensing other physiological signals and/or delivering therapies in addition to the neural stimulation. Examples of such additional therapies include cardiac pacing therapy, cardioversion/defibrillation therapy, cardiac resynchronization therapy (CRT), cardiac remodeling control therapy (RCT), drug therapy, cell therapy, and gene therapy. In various embodiments, implantablemedical device 110 delivers the neural stimulation in coordination with one or more such additional therapies. In one embodiment, in addition to lead 112,system 100 includes one or more endocardial and/or epicardial leads for delivering pacing and/or defibrillation pulses to the heart. -
Lead 112 is an implantable neural stimulation lead including aproximal end 114, a distal end 116, and an elongatelead body 118 betweenproximal end 114 and distal end 116.Proximal end 114 is coupled to implantablemedical device 110. Distal end 116 includes at least one stimulation electrode for delivering the neural stimulation pulses to a target region of the nervous system ofbody 101. In one embodiment, as illustrated inFIG. 1 , distal end 116 includesstimulation electrodes 120 and 122. In various other embodiments, distal end 116 includes one stimulation electrode or three or more stimulation electrodes. In one embodiment, a reference electrode is incorporated onto implantablemedical device 110. In a specific embodiment, implantablemedical device 110 includes a hermetically sealed conductive housing that functions as the reference electrode. Neural stimulation pulses are delivered using (i) two stimulation electrodes in distal end 116 (electrodes 120 or 122), or (ii) a stimulation electrode (electrode 120 or 122) in distal end 116 and the reference electrode on implantablemedical device 110. In various embodiments, one or more of the stimulation electrodes are also used for sensing one or more neural signals. The distal portion of elongate lead body 118 (a substantial portion of elongatelead body 118 coupled to distal end 116) is configured for placement insubclavian vein 102 andthoracic duct 105, such that distal end 116 is placed inthoracic duct 105. During the implantation oflead 112, distal end 116 is inserted intosubclavian vein 102 through an incision, advanced insubclavian vein 102 towardthoracic duct 105, inserted intothoracic duct 105 fromsubclavian vein 102, and advanced inthoracic duct 105 until a predetermined location inthoracic duct 105 is reached. In one embodiment, the position of distal end 116 is adjusted by delivering test neural stimulation pulses and detecting evoked neural signals and/or other physiological responses. In one embodiment, lead 112 includes a fixation mechanism configured to stabilize distal end 116 in the determined position inthoracic duct 105. Implantablemedical device 110 is connected toproximal end 114 and is subcutaneously implanted. One example of method and apparatus for accessing the lymphatic system is discussed in U.S. patent application Ser. No., ______, entitled “METHOD AND APPARATUS FOR LYMPHATIC SYSTEM PACING AND SENSING,” filed on even date herewith (Attorney Docket No. 279.A69 μl), assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety. Specific examples of electrode configurations and placement are also discussed in detail below, with reference toFIGS. 9-12 . - In one embodiment, lead 112 is configured such that distal end 116 can be further advanced into a lymphatic vessel branching from
thoracic duct 105, such as the gastric branch, so that the stimulation electrode can be placed in close proximity of a desirable target region. After the distal end 116 is inserted intothoracic duct 105, it is advanced to the junction ofthoracic duct 105 and the branching lymphatic vessel and inserted to the branching lymphatic vessel. While the placement of at least one stimulation electrode in the thoracic duct is specifically discussed as an example of providing for access to a target region, the present subject matter generally includes introducing one or more stimulus delivery devices such as one or more stimulation electrodes to a stimulation site via a lymphatic vessel. In various embodiments, neural stimulation pulses are delivered through one or more stimulation electrodes placed in the lymphatic vessel and/or one or more stimulation electrodes placed in a structure that is accessible through the lymphatic vessel, including another lymphatic vessel branching from the lymphatic vessel. - In one embodiment,
system 100 includes two or more leads each including one or more stimulation electrodes arranged to be placed inthoracic duct 105. In another embodiment, a lead includes a plurality of electrodes arranged for delivering independently controllable neural stimulation pulses to two or more target regions. -
External system 130 communicates with implantablemedical device 110 and provides for access to implantablemedical device 110 by a physician or other caregiver. In one embodiment,external system 130 includes a programmer. In another embodiment,external system 130 is a patient management system including an external device communicating with implantablemedical device 110 viatelemetry link 125, a remote device in a relatively distant location, and a telecommunication network linking the external device and the remote device. The patient management system allows access to implantablemedical device 110 from a remote location, for purposes such as monitoring patient status and adjusting therapies. In one embodiment,telemetry link 125 is an inductive telemetry link. In another embodiment,telemetry link 125 is a far-field radio-frequency (RF) telemetry link.Telemetry link 125 provides for data transmission from implantablemedical device 110 toexternal system 130. This includes, for example, transmitting real-time physiological data acquired by implantablemedical device 110, extracting physiological data acquired by and stored in implantablemedical device 110, extracting patient history data such as occurrences of predetermined types of pathological events and therapy deliveries recorded in implantablemedical device 110, and/or extracting data indicating an operational status of implantable medical device 110 (e.g., battery status and lead impedance).Telemetry link 125 also provides for data transmission fromexternal system 130 to implantablemedical device 110. This includes, for example, programming implantablemedical device 110 to acquire physiological data, programming implantablemedical device 110 to perform at least one self-diagnostic test (such as for a device operational status), and/or programming implantablemedical device 110 to deliver one or more therapies and/or to adjust the delivery of one or more therapies. -
FIG. 2 is an illustration of an embodiment of aneural stimulation system 200 and portions of the environment in whichsystem 200 is used.System 200 includes the components ofneural stimulation system 100 and an additional lead. That is,neural stimulation system 200 includes implantablemedical device 110, leads 112 and 232,external system 130, andtelemetry link 125. -
Lead 232 is an implantable neural stimulation lead including a proximal end 234, adistal end 236, and an elongatelead body 238 between proximal end 234 anddistal end 236. Proximal end 234 is coupled to implantablemedical device 110.Distal end 236 includes at least one electrode. In one embodiment, as illustrated inFIG. 2 , lead 232 includes anelectrode 240 atdistal end 236. In another embodiment, lead 232 includes a plurality of stimulation electrodes. In one embodiment, lead 232 is configured for subcutaneous placement, external tothoracic duct 105. In one embodiment,electrode 240 is used as a reference electrode. -
Lead 232 expands the range of target regions to which neural stimulation pulses can be delivered from implantablemedical device 110. In various embodiments, neural stimulation pulses are delivered through any pair of electrodes ofsystem 200 including (i) two stimulation electrodes in distal end 116 (electrodes 120 and 122), (ii) a stimulation electrode in distal end 116 (electrode 120 or 122) and electrode 240 (as the reference electrode), or (iii) a stimulation electrode in distal end 116 (electrode 120 or 122) and the reference electrode on implantablemedical device 110. In one embodiment, distal ends 116 and 236 are positioned such as a target structure for the neural stimulation is approximately between a stimulation electrode in distal end 116 (electrode 120 or 122) and a reference electrode (electrode 240 or the reference electrode on implantable medical device 110). For example, the target structure is a portion of the spinal cord ofbody 101. -
FIG. 3 is a block diagram illustrating an embodiment of an implantablemedical device 310, which is a specific embodiment of implantablemedical device 110. Implantablemedical device 310 includes aneural stimulation circuit 346 and animplant control circuit 348.Neural stimulation circuit 346 delivers neural stimulation pulses to a pair ofstimulation electrodes stimulation electrodes thoracic duct 105.Implant control circuit 348 controls the delivery of the neural stimulation pulses fromneural stimulation circuit 346. - In one embodiment,
stimulation electrodes thoracic duct 105 and adjacent to the target region, such aselectrodes 120 and 122. In another embodiment,stimulation electrode 342 is inthoracic duct 105 and adjacent to the target region, such aselectrode 120 or 122, andstimulation electrode 344 is external tothoracic duct 105, such aselectrode 240 or a reference electrode on implantablemedical device 310. In one embodiment, the target region is approximately betweenstimulation electrodes - In various embodiments, the target region includes one or more components of the nervous system that are adjacent to the thoracic duct in the posterior mediastinal region or abdominal region. Examples of the target region include the sympathetic nerves, the parasympathetic nerves (including the vagus nerve), the phrenic nerve, the spinal cord, the brain stem, the renal nerves, and the baroreceptors in the carotid artery and aorta. In one embodiment, cardiac functions are regulated by applying neural stimulation including one or more of sympathetic excitation, sympathetic inhibition, parasympathetic excitation, and parasympathetic inhibition. One example of a system capable of providing excitatory stimulation and inhibitory stimulation to both sympathetic nerves and parasympathetic nerves is discussed in U.S. patent application Ser. No. 11/124,791, entitled “METHOD AND APPARATUS FOR CONTROLLING AUTONOMIC BALANCE USING NEURAL STIMULATION,” filed on May 9, 2005, assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety.
- For illustration purposes,
FIG. 3 shows the pair ofstimulation electrodes neural stimulation circuit 346 delivers neural stimulation pulses through one or more pairs of stimulation electrodes selected from a plurality of stimulation electrodes. In one embodiment,neural stimulation circuit 346 includes two or more stimulation output channels each delivering neural stimulation pulses through a pair of stimulation electrodes. In another embodiment, an electrode array with a plurality of stimulation electrodes is placed in the thoracic duct, and one or more stimulation electrodes are selected for delivering neural stimulation pulses by testing the physiological effect of stimulation associated with each stimulation electrode. -
FIG. 4 is a block diagram illustrating an embodiment of an implantablemedical device 410, which is another specific embodiment of implantablemedical device 110. Implantablemedical device 410 includesneural stimulation circuit 346, asensing circuit 452, animplant control circuit 448, and animplant telemetry circuit 458. One or morephysiological sensors 450 are housed within implantablemedical device 410, incorporated onto implantablemedical device 410, and/or connected to implantablemedical device 410 using a lead. - Physiological sensor(s) 450 sense one or more physiological signals indicative of neural function and/or physiological functions regulated by the components of the nervous system to be stimulated.
Sensing circuit 452 processes the one or more physiological signals and produces signals indicative of a need to start, stop, or adjust the neural stimulation. Examples of such physiological signals include signals indicative of heart rate, heart rate variability (HRV), and blood pressure. In one embodiment, physiological sensor(s) 450 include one or both ofstimulation electrodes -
Implant control circuit 448 is a specific embodiment ofimplant control circuit 348 and controls the delivery of the neural stimulation pulses fromneural stimulation circuit 346 using a plurality of stimulation parameters.Implant control circuit 448 includes aparameter storage circuit 454 and aparameter receiver 456.Parameter storage circuit 454 stores values of the plurality of stimulation parameters. Examples of such stimulation parameters include pulse amplitude, pulse width, and pulse frequency (or inter-pulse interval). The values of the plurality of stimulation parameters are adjustable.Parameter receiver 456 receives values of the plurality of stimulation parameters and updatesparameter storage circuit 454 with the received values. In one embodiment,implant control circuit 448 controls the delivery of the neural stimulation pulses fromneural stimulation circuit 346 using one or more physiological signals sensed by physiological sensor(s) 450. In various embodiments, each sensed physiological signal is used as one or more of a triggering signal to start or stop the neural stimulation, a safety assurance signal to start, stop, or adjust the intensity of the neural stimulation, and a feedback signal to provide closed-loop neural stimulation. -
Implant telemetry circuit 458 transmits and receives data viatelemetry link 125. In one embodiment, the values of the plurality of stimulation parameters are externally programmable, and the programmed values are received fromexternal system 130 throughtelemetry link 125. -
FIG. 5 is a block diagram illustrating an implantablemedical device 510, which is a specific embodiment of implantablemedical device 410. Implantablemedical device 510 includesneural stimulation circuit 346, aneural sensing circuit 552, animplant control circuit 548, andimplant telemetry circuit 458. -
Neural sensing circuit 552 is a specific embodiment ofsensing circuit 452 and processes a neural signal sensed usingneural sensing electrodes neural sensing circuit 552 processes two or more neural signals sensed using additional neural sensing electrodes. In one embodiment, the neural signal is sensed from the same site to which the neural stimulation pulses are delivered, andstimulation electrodes neural sensing electrodes stimulation electrodes neural sensing electrodes stimulation electrodes neural sensing electrodes -
Implant control circuit 548 is a specific embodiment ofimplant control circuit 448 and includes a closed-loop controller 560,parameter storage circuit 454, andparameter receiver 456.Implant control circuit 548 controls the delivery of the neural stimulation pulses fromneural stimulation circuit 346 using a plurality of stimulation parameters and the sensed and processed neural signal. Closed-loop controller 560 controls the delivery of the neural stimulation pulses using the sensed and processed neural signal as an input for feedback control. Examples of closed-loop neural stimulation are discussed in U.S. patent application Ser. No. 11/280,940, entitled “SYSTEM AND METHOD FOR CLOSED-LOOP NEURAL STIMULATION,” filed on Nov. 16, 2005, assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety. -
FIG. 6 is a block diagram illustrating an embodiment of anexternal system 630, which is a specific embodiment ofexternal system 130.External system 630 includes anexternal telemetry circuit 670, anexternal controller 672, and auser interface 674.External telemetry circuit 670 transmits and receives data viatelemetry link 125.External controller 672 controls the operation ofexternal system 630.User interface 674 allows a user such as a physician or other caregiver to communicate with implantablemedical device 110 throughexternal system 630.User interface 674 includes apresentation device 676 and auser input device 678.User input device 678 allows for the programming of the values of the plurality of stimulation parameters. In one embodiment,presentation device 676 anduser input device 678 are integrated or partially integrated to include an interactive screen allowing for programming of implantablemedical device 110. - In one embodiment,
external system 630 includes a programmer. In another embodiment,external system 630 includes a patient management system as discussed below with reference toFIG. 7 . -
FIG. 7 a block diagram illustrating an embodiment of anexternal system 730, which is a specific embodiment ofexternal system 630. As illustrated inFIG. 7 ,external system 730 is a patient management system including anexternal device 780, atelecommunication network 782, and aremote device 784.External device 780 is placed within the vicinity of implantablemedical device 110 and includesexternal telemetry system 670 to communicate with the implantable medical device viatelemetry link 125.Remote device 784 is in a remote location and communicates withexternal device 780 throughnetwork 782.Remote device 784 includesuser interface 674 to allow the physician or other caregiver to monitor and treat a patient from a distant location and/or allowing access to various treatment resources from the remote location. -
FIG. 8 is a flow chart illustrating a method for delivering neural stimulation via the thoracic duct. In one embodiment, the method is performed usingsystem 100 orsystem 200, including the various embodiments of their components discussed above. - A neural stimulation lead is inserted into a lymphatic vessel of a patient at 800. In one embodiment, this lymphatic vessel is the thoracic duct. The neural stimulation lead is an implantable transluminal lead having a proximal end configured for connection to an implantable medical device and a distal end including one or more stimulation electrodes. To insert the neural stimulation lead into the thoracic duct such that neural stimulation pulses can be delivered through the stimulation electrode(s), an opening is made on the subclavian vein, upstream from the junction of the subclavian vein and the ostium of the thoracic duct. The distal end of the neural stimulation lead is inserted into the subclavian vein through the opening and advanced toward the junction of the subclavian vein and the ostium of the thoracic duct downstream. Then, the neural stimulation lead is guided into the thoracic duct and advanced in the thoracic duct until the distal end reaches a region determined by the target to which the neural stimulation pulses are delivered. Examples of the target region include any nerve of other components of the nervous system in the mediastinal or abdominal region, adjacent to the thoracic duct, such as sympathetic nerves, parasympathetic nerves including the vagus nerve, the phrenic nerve, renal nerves, the spinal cord, the brain stem, and baroreceptors in the carotid artery and aorta. In one embodiment, to further approach a desirable target region, the distal end of the neural stimulation lead is guided into a lymphatic vessel branching from the thoracic duct.
- The stimulation electrode(s) of the neural stimulation lead are positioned in the lymphatic vessel, such as the thoracic duct or the lymphatic vessel branching from the thoracic duct, at 810. In one embodiment, after the distal end of the neural stimulation lead reaches the region determined by the target, test neural stimulation pulses are delivered. The distal end is moved in the thoracic duct or the lymphatic vessel branching from the thoracic duct until it reaches a position identified by detecting satisfactory responses to the stimulation, such as evoked neural signals and/or other anticipated physiological effects. The distal end with the stimulation electrode(s) is then stabilized in that position. In another embodiment, the neural stimulation lead includes a plurality of stimulation electrodes. After the neural stimulation lead is inserted, test neural stimulation pulses are delivered to different stimulation electrodes or different combinations of the stimulation electrodes, one at a time. A stimulation electrode or a combination of stimulation electrodes is identified for an intended therapy based on the responses to the stimulation, such as evoked neural signals and/or other anticipated physiological effects.
- One or more physiological signals are sensed at 820. In one embodiment, at least one physiological signal is sensed to indicate a need to start, stop, or adjust the delivery of the neural stimulation. In another embodiment, at least one physiological signal is sensed for monitoring, diagnostic, and/or therapeutic purposes other then the neural stimulation. In one embodiment, one or more neural signals are sensed. In a specific embodiment, a neural signal is sensed from the nerve to which the neural stimulation is delivered. In another embodiment, one or more signals each indicative of a physiological function regulated by the stimulated nerve are sensed.
- Neural stimulation pulses are delivered using the stimulation electrode(s) positioned in the lymphatic vessel, such as the thoracic duct or the lymphatic vessel branching from the thoracic duct, at 830. In one embodiment, the neural stimulation pulses are delivered through two stimulation electrodes positioned in the thoracic duct or the lymphatic vessel branching from the thoracic duct. In another embodiment, the neural stimulation pulses are delivered using a stimulation electrode positioned in the thoracic duct or the lymphatic vessel branching from the thoracic duct and another stimulation electrode positioned in a location in the body external to the lymphatic vessels. In a specific embodiment, the neural stimulation pulses are delivered to a portion of the nervous system approximately between a pair of stimulation electrodes. The delivery of the neural stimulation pulses is controlled using a plurality of stimulation parameters. Examples of the stimulation parameters include pulse amplitude, pulse width, and pulse frequency (or inter-pulse interval). These stimulation parameters are adjustable. In one embodiment, a user such as a physician or other caregiver programs one or more values of the plurality of stimulation parameters. In one embodiment, the delivery of the neural stimulation pulses are also controlled using the one or more physiological signals, including the one or more neural signals.
- The neural stimulation pulses are delivered via the thoracic duct or the lymphatic vessel branching from the thoracic duct to treat one or more clinical conditions each associated with a physiological function regulated by a nerve or other component of the nervous system that is adjacent the thoracic duct or the lymphatic vessel branching from the thoracic duct. Examples of such clinical conditions include respiratory disorders, abnormal blood pressure, cardiac arrhythmias, myocardial infarction or ischemic insult (angina), heart failure, epilepsy, depression, renal disorders, pain, migraine, obesity, movement disorders, and incontinence. Specific examples of the treatment include (i) treatment of hypertension by baroreceptor stimulation, (ii) treatment of heart failure by sympathetic inhibition or vagal excitation; (iii) control of post-myocardial infarction remodeling by sympathetic inhibition or vagal excitation, (iv) mitigation of chronic pain by neural activation or blocking, (v) treatment of vascular pain including refractory angina and peripheral vascular diseases (PVD) by spinal cord stimulation, (vi) treatment of rachidian pain including failed back surgery syndrome (FBSS), degenerative low back leg pain (LBLP), nerve root lesions, incomplete spine lesions and spinal stenosis by spinal cord stimulation, (vii) treatment of type 1 or type 2 chronic regional pain syndrome (CRPS) by spinal cord stimulation, and (viii) treatment of perineal pain and urological diseases by spinal cord stimulation, and restoration of lower extremity motor functions such as standing and walking after spinal cord injury by ventral spinal cord stimulation.
-
FIGS. 9-13 illustrate, by way of example, various embodiments of an electrode assembly for placement in the lymphatic vessel to allow for the neural stimulation. The electrode assembly includes one or more electrode bases. One or more stimulation electrodes are incorporated onto and/or integrated with each of the one or more electrode bases. In one embodiment, the one or more electrode bases each are formed as portion of a lead such aslead 112. In one specific embodiment, an electrode base is formed at distal end 116 oflead 112, andstimulation electrodes 120 and 122 are on that electrode base. In another specific embodiment, one or more electrode bases are formed in elongatelead body 118 oflead 112. In another embodiment, electrode bases are formed at distal end 116 and elongatelead body 118 oflead 112 to provide for delivery of the neural stimulation pulses to multiple target regions. -
FIG. 9 is an illustration of alymphatic vessel 905 and atarget region 907 in their natural state.Target region 907 is a region in the nervous system to which the neural stimulation pulses are delivered. As illustrated inFIG. 9 ,lymphatic vessel 905 andtarget region 907 are not in direct contact, or not constantly in direct contact, with each other in their natural state. Electrode assemblies illustrated inFIGS. 10-13 each cause and maintain a substantially constant and direct contact betweenlymphatic vessel 905 andtarget region 907 by substantially altering the natural path oflymphatic vessel 905. Such a substantially constant and direct contact allows for a reliable delivery of neural stimulation pulses from one or more electrodes inlymphatic vessel 905 to targetregion 907. In various embodiments,lymphatic vessel 905 represents one of the thoracic duct, a vessel branching from the thoracic duct, or any lymphatic vessel suitable for placement of the one or more electrodes for the delivery of the neural stimulation pulses. -
FIG. 10 is an illustration of an embodiment of an electrode assembly including anelectrode base 1021 configured to be implanted inlymphatic vessel 905 and astimulation electrode 1020 onelectrode base 1021.Electrode base 1021 has an elongate shape and includes a bias configured to cause a portion oflymphatic vessel 905 to substantially alter its natural path to contacttarget region 907. The bias also allowselectrode 1020 to be in contact with the inner wall oflymphatic vessel 905 for delivering the neural stimulation pulses to targetregion 907.Electrode base 1021 has a stiffness allowing for stabilizing the position ofstimulation electrode 1020 inlymphatic vessel 905 and maintaining the contact between the portion oflymphatic vessel 905 andtarget region 907 after implantation. In one embodiment,electrode base 1021 is in a helical form. In one embodiment,electrode base 1021 includes an elongate body having shape memory characteristics such that it returns to its preformed shape after the implantation procedure during which a stylet or guide wire may be used. The shape memory characteristics are provided by using a shape memory polymer such as polyether polyurethane or a shape memory metal. In one embodiment, the electrode assembly is coupled to implantablemedical device 110 via a lead such aslead 112. In a specific embodiment,electrode base 1021 is formed at distal end 116 oflead 112, withstimulation electrode 1020 being stimulation electrode 120. In other specific embodiments, two or more stimulation electrodes are incorporated intoelectrode base 1021. -
FIG. 11 is an illustration of an embodiment of another electrode assembly including anelectrode base 1121 configured to be implanted inlymphatic vessel 905 andstimulation electrodes electrode base 1121.Electrode base 1121 has an elongate shape and includes a bias configured to cause a portion oflymphatic vessel 905 to substantially alter its natural path to contacttarget region 907. The bias also allowselectrodes lymphatic vessel 905 for delivering the neural stimulation pulses to targetregion 907 using either or both ofelectrodes Electrode base 1121 has the stiffness allowing for stabilizing the positions ofstimulation electrodes lymphatic vessel 905 and maintaining the contact between the portion oflymphatic vessel 905 andtarget region 907 after implantation. In one embodiment,electrode base 1121 is in a helical form. In one embodiment,electrode base 1121 includes an elongate body having shape memory characteristics such that it returns to its preformed shape after the implantation procedure during which a stylet or guide wire may be used. The shape memory characteristics are provided by using a shape memory polymer such as polyether polyurethane or a shape memory metal. In one embodiment, the electrode assembly is coupled to implantablemedical device 110 via a lead such aslead 112. In a specific embodiment,electrode base 1121 is formed at distal end 116 oflead 112, withstimulation electrodes stimulation electrodes 120 and 122. In other specific embodiments, one stimulation electrode, or three or more stimulation electrodes, are incorporated intoelectrode base 1121. -
FIG. 12 is an illustration of an embodiment of another electrode assembly including anelectrode base 1121 withstimulation electrodes electrode base 1221 withstimulation electrodes Electrode bases lymphatic vessel 905.Electrode bases 1121 has the elongate shape and includes the bias configured to cause a portion oflymphatic vessel 905 to substantially alter its natural path to contacttarget region 907. The bias also allowselectrodes lymphatic vessel 905 for delivering neural stimulation pulses to targetregion 907 using either or both ofelectrodes Electrode bases 1221 has an elongate shape and includes a bias configured to cause a portion oflymphatic vessel 905 to substantially alter its natural path to contact atarget region 1207. The bias also allowselectrodes lymphatic vessel 905 for delivering neural stimulation pulses to targetregion 1207 using either or both ofelectrodes Electrode bases lymphatic vessel 905 and maintaining the contact between the portion oflymphatic vessel 905 andtarget region 907 after implantation. In one embodiment,electrode bases electrode bases medical device 110 via a lead such aslead 112. In a specific embodiment,electrode base 1121 is formed at distal end 116 oflead 112, withstimulation electrodes stimulation electrodes 120 and 122, andelectrode base 1221 is formed in elongatelead body 118 oflead 112. In other specific embodiments, one stimulation electrode, or three or more stimulation electrodes, are incorporated into each ofelectrode bases -
FIG. 13 is an illustration of an embodiment of another electrode assembly including anelectrode base 1321 and astimulation electrode 1320.Electrode base 1321 is expandable. After being expanded,electrode base 1321 causes a portion oflymphatic vessel 905 to substantially expand to contacttarget region 907. The expansion ofelectrode base 1321 also allowselectrode 1320 to be in stable contact with the inner wall oflymphatic vessel 905 for delivering neural stimulation pulses to targetregion 907. In one embodiment,electrode base 1321 includes a stent that is expanded in the lymphatic vessel to maintain patency of the vessel. In one embodiment,stimulation electrode 1320 is incorporated into the stent. In another embodiment, the stent is made of metal and functions asstimulation electrode 1320. In another embodiment,stimulation electrode 1320 is integrated into the stent to be a portion of its structure. The stent also stabilize the position ofstimulation electrode 1320 inlymphatic vessel 905 and prevents obstruction of the lymphatic flow. In one embodiment, the electrode assembly is coupled to implantablemedical device 110 via a lead such aslead 112. In a specific embodiment, the stent is incorporated into distal end 116 oflead 112. In another embodiment, the stent is incorporated into elongatelead body 118 oflead 112. In another embodiment, two or more stents are incorporated into elongatelead body 118 and/or distal end 116 oflead 112. - It is to be understood that the above detailed description is intended to be illustrative, and not restrictive. Other embodiments will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Claims (33)
1. A system for delivering neural stimulation to a target region in a body having lymphatic vessels, the system comprising:
a first electrode assembly including a first electrode base configured to be implanted into one of the lymphatic vessels and a first stimulation electrode on the first electrode base, the first electrode base configured to cause a portion of the one of the lymphatic vessels to substantially alter its natural path to contact the target region and maintain the contact between the portion of the one of the lymphatic vessels and the target region after an implantation of the first electrode assembly; and
an implantable medical device including a neural stimulation circuit adapted to deliver neural stimulation pulses through the first stimulation electrode.
2. The system of claim 1 , wherein the first electrode base comprises an elongate electrode base including one or more biases each configured to cause the portion of the one of the lymphatic vessels to substantially alter its natural path to contact the target region, the elongate electrode base having a stiffness allowing for maintaining the contact between the portion of the one of the lymphatic vessels and the target region after the implantation of the first electrode assembly.
3. The system of claim 1 , wherein the first electrode base comprises an expandable electrode base configured to cause the portion of the one of the lymphatic vessels to substantially alter its natural path to contact the target region, after being expanded.
4. The system of claim 3 , wherein the expandable electrode base comprises a stent, and the first electrode is incorporated into or integrated with the stent.
5. The system of claim 1 , further comprising a first implantable lead having a first distal end, a first proximal end configured to be connected to the implantable medical device, and a first elongate lead body between the first distal end and the first proximal end, and wherein the first electrode assembly is incorporated into the first implantable lead.
6. The system of claim 5 , wherein the first electrode assembly is incorporated into the first distal end.
7. The system of claim 5 , wherein the first electrode assembly is incorporated into the first elongate lead body.
8. The system of claim 5 , wherein the first electrode base further comprises a second stimulation electrode, and the neural stimulation circuit is adapted to deliver the neural stimulation pulses through the first stimulation electrode and the second stimulation electrode.
9. The system of claim 5 , further comprising a second stimulation electrode configured to be placed in a location external to the lymphatic vessels, and wherein the neural stimulation circuit is adapted to deliver the neural stimulation pulses through the first stimulation electrode and the second stimulation electrode.
10. The system of claim 9 , further comprising a second implantable lead configured to be subcutaneously implanted, the second implantable lead having a second distal end including the second stimulation electrode, a second proximal end configured to be connected to the implantable medical device, and a second elongate lead body between the distal end and the proximal end.
11. The system of claim 9 , wherein the second stimulation electrode is incorporated onto the implantable medical device.
12. The system of claim 5 , comprising a physiological sensor adapted to sense a physiological signal, and wherein the implantable medical device comprises:
a sensing circuit, coupled to the physiological sensor, to process the physiological signal; and
an implant control circuit adapted to control the delivery of the neural stimulation pulses using the physiological signal.
13. The system of claim 12 , wherein the physiological sensor comprises an neural sensing electrode configured to sense a neural signal, the sensing circuit comprises a neural sensing circuit to process the neural signal, and the implant control circuit is adapted to control the delivery of the neural stimulation pulses using the processed neural signal.
14. The system of claim 13 , wherein the neural sensing electrode is the first stimulation electrode.
15. The system of claim 13 , wherein the implant control circuit comprises a closed-loop controller adapted to provide feedback control of the delivery of the neural stimulation pulses using the sensed neural signal as an input signal.
16. The system of claim 5 , wherein the implantable medical device comprises an implant control circuit adapted to control the delivery of the neural stimulation pulses using a plurality of stimulation parameters, the implant control circuit including:
a parameter storage circuit to store values of the plurality of stimulation parameters; and
a parameter receiver to receive one or more programmed values of the plurality of stimulation parameters and to update the parameter storage circuit with the received one or more programmed values of the plurality of stimulation parameters.
17. The system of claim 16 , wherein the implantable medical device comprises an implant telemetry circuit to receive the one or more programmed values of the plurality of stimulation parameters.
18. The system of claim 17 , further comprising an external system communicatively coupled to the implantable medical device, the external system including:
a user input device adapted to allow programming of the one or more programmed values of the parameters; and
an external telemetry circuit to transmit the one or more programmed values of the plurality of stimulation parameters to the implantable medical device.
19. A method for delivering neural stimulation to a body having lymphatic vessels including a thoracic duct, the method comprising:
delivering neural stimulation pulses from an implantable medical device to at least a first stimulation electrode placed in one of the lymphatic vessels.
20. The method of claim 19 , further comprising altering a natural path of the one of the lymphatic vessels to cause a portion of the one of the lymphatic vessels to contact a target region to which the neural stimulation are delivered using an electrode base configured to be implanted in the one of the lymphatic vessels, and wherein the first stimulation electrode is incorporated into or integrated with the electrode base.
21. The method of claim 19 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses through a stimulation electrode placed in the thoracic duct.
22. The method of claim 19 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses through a stimulation electrode placed in one of the vessels branching from the thoracic duct.
23. The method of claim 19 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses through the first stimulation electrode and a second stimulation electrode placed in the one of the lymphatic vessels.
24. The method of claim 19 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses through the first stimulation electrode and a second stimulation electrode placed in a location in the body external the lymphatic vessels.
25. The method of claim 19 , further comprising:
sensing one or more physiological signals; and
controlling the delivery of the neural stimulation pulses using the one or more physiological signals.
26. The method of claim 25 , wherein sensing the one or more physiological signals comprises sensing a neural signal using the first stimulation electrode, and controlling the delivery of the neural stimulation pulses comprises controlling the delivery of the neural stimulation pulses using the neural signal.
27. The method of claim 19 , further comprising:
controlling the delivery of the neural stimulation pulses using a plurality of stimulation parameters;
receiving one or more values of the plurality of stimulation parameters; and
storing the received one or more values of the plurality of the stimulation parameters.
28. The method of claim 27 , further comprising programming one or more values of the stimulation parameters according to a target to which the neural stimulation pulses are delivered, the target including one or more component of a nervous system.
29. The method of claim 28 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses to a parasympathetic nerve.
30. The method of claim 29 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses to a vagus nerve.
31. The method of claim 28 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses to a sympathetic nerve.
32. The method of claim 28 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses to a spinal cord.
33. The method of claim 28 , wherein delivering the neural stimulation pulses comprises delivering the neural stimulation pulses to baroreceptors.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/422,421 US20070282376A1 (en) | 2006-06-06 | 2006-06-06 | Method and apparatus for neural stimulation via the lymphatic system |
EP07797400A EP2032202A2 (en) | 2006-06-06 | 2007-05-10 | System for neural stimulation via lymphatic vessel |
PCT/US2007/068617 WO2007146517A2 (en) | 2006-06-06 | 2007-05-10 | System for neural stimulation via lymphatic vessel |
JP2009514448A JP2009539492A (en) | 2006-06-06 | 2007-05-10 | System for neural stimulation via lymphatic vessels |
US12/604,233 US8369943B2 (en) | 2006-06-06 | 2009-10-22 | Method and apparatus for neural stimulation via the lymphatic system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/422,421 US20070282376A1 (en) | 2006-06-06 | 2006-06-06 | Method and apparatus for neural stimulation via the lymphatic system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/604,233 Division US8369943B2 (en) | 2006-06-06 | 2009-10-22 | Method and apparatus for neural stimulation via the lymphatic system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070282376A1 true US20070282376A1 (en) | 2007-12-06 |
Family
ID=38791288
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/422,421 Abandoned US20070282376A1 (en) | 2006-06-06 | 2006-06-06 | Method and apparatus for neural stimulation via the lymphatic system |
US12/604,233 Expired - Fee Related US8369943B2 (en) | 2006-06-06 | 2009-10-22 | Method and apparatus for neural stimulation via the lymphatic system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/604,233 Expired - Fee Related US8369943B2 (en) | 2006-06-06 | 2009-10-22 | Method and apparatus for neural stimulation via the lymphatic system |
Country Status (4)
Country | Link |
---|---|
US (2) | US20070282376A1 (en) |
EP (1) | EP2032202A2 (en) |
JP (1) | JP2009539492A (en) |
WO (1) | WO2007146517A2 (en) |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070282382A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and device for lymphatic system monitoring |
US20080195171A1 (en) * | 2007-02-13 | 2008-08-14 | Sharma Virender K | Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System |
US20080234556A1 (en) * | 2007-03-20 | 2008-09-25 | Cardiac Pacemakers, Inc. | Method and apparatus for sensing respiratory activities using sensor in lymphatic system |
US20100076279A1 (en) * | 2008-09-23 | 2010-03-25 | Shuros Allan C | Method and apparatus for organ specific inflammation monitoring |
US7734341B2 (en) * | 2006-06-06 | 2010-06-08 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20100228310A1 (en) * | 2009-03-09 | 2010-09-09 | Shuros Allan C | Systems and methods for autonomic nerve modulation |
US20100256700A1 (en) * | 2009-04-07 | 2010-10-07 | Shuros Allan C | Method and apparatus for organ specific inflammation therapy |
US7894906B2 (en) | 2006-06-06 | 2011-02-22 | Cardiac Pacemakers, Inc. | Amelioration of chronic pain by endolymphatic stimulation |
US8126538B2 (en) | 2006-06-06 | 2012-02-28 | Cardiac Pacemakers, Inc. | Method and apparatus for introducing endolymphatic instrumentation |
US8131372B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Renal nerve stimulation method for treatment of patients |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
US8369943B2 (en) | 2006-06-06 | 2013-02-05 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation via the lymphatic system |
US8433423B2 (en) | 2004-10-05 | 2013-04-30 | Ardian, Inc. | Methods for multi-vessel renal neuromodulation |
US8454594B2 (en) | 2002-04-08 | 2013-06-04 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8548600B2 (en) | 2002-04-08 | 2013-10-01 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatuses for renal neuromodulation and associated systems and methods |
US8620423B2 (en) | 2002-04-08 | 2013-12-31 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermal modulation of nerves contributing to renal function |
US8626300B2 (en) | 2002-04-08 | 2014-01-07 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for thermally-induced renal neuromodulation |
US8684998B2 (en) | 2002-04-08 | 2014-04-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for inhibiting renal nerve activity |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US8771252B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8818514B2 (en) | 2002-04-08 | 2014-08-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for intravascularly-induced neuromodulation |
US8905999B2 (en) | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
US8958871B2 (en) | 2002-04-08 | 2015-02-17 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
US9192715B2 (en) | 2002-04-08 | 2015-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal nerve blocking |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9327122B2 (en) | 2002-04-08 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9439726B2 (en) | 2002-04-08 | 2016-09-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10080864B2 (en) | 2012-10-19 | 2018-09-25 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for catheter treatment devices and associated devices, systems, and methods |
US10179020B2 (en) | 2010-10-25 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems and methods for evaluation and feedback of neuromodulation treatment |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10376694B2 (en) | 2008-10-09 | 2019-08-13 | Virender K. Sharma | Method and apparatus for stimulating the vascular system |
US10537385B2 (en) | 2008-12-31 | 2020-01-21 | Medtronic Ardian Luxembourg S.A.R.L. | Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility |
US10603489B2 (en) | 2008-10-09 | 2020-03-31 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
CN111481830A (en) * | 2020-04-24 | 2020-08-04 | 上海交通大学 | Closed-loop electrical nerve stimulation system and method for setting parameters of closed-loop electrical nerve stimulation |
US10874455B2 (en) | 2012-03-08 | 2020-12-29 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US11040199B2 (en) * | 2016-04-04 | 2021-06-22 | General Electric Company | Techniques for neuromodulation |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
US11338140B2 (en) | 2012-03-08 | 2022-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring of neuromodulation using biomarkers |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
WO2024239607A1 (en) * | 2023-05-19 | 2024-11-28 | 深圳先进技术研究院 | Lymph node regulation and control system and method |
US12179014B2 (en) * | 2005-11-18 | 2024-12-31 | Zoll Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US12201836B2 (en) | 2021-06-08 | 2025-01-21 | General Electric Company | Techniques for neuromodulation |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080103572A1 (en) | 2006-10-31 | 2008-05-01 | Medtronic, Inc. | Implantable medical lead with threaded fixation |
US20080294228A1 (en) * | 2007-05-23 | 2008-11-27 | Cardiac Pacemakers | Method and device for controlled stimulation of lymphatic flow |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8600505B2 (en) | 2011-12-07 | 2013-12-03 | Cyberonics, Inc. | Implantable device for facilitating control of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8577458B1 (en) | 2011-12-07 | 2013-11-05 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring |
US8918191B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US8630709B2 (en) | 2011-12-07 | 2014-01-14 | Cyberonics, Inc. | Computer-implemented system and method for selecting therapy profiles of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US10188856B1 (en) | 2011-12-07 | 2019-01-29 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8918190B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction |
US8700150B2 (en) | 2012-01-17 | 2014-04-15 | Cyberonics, Inc. | Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US8571654B2 (en) | 2012-01-17 | 2013-10-29 | Cyberonics, Inc. | Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction |
US8688212B2 (en) | 2012-07-20 | 2014-04-01 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation |
WO2014036449A1 (en) | 2012-08-31 | 2014-03-06 | Alfred E. Mann Foundation For Scientific Research | Feedback controlled coil driver for inductive power transfer |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
EP2914192B1 (en) | 2012-11-05 | 2019-05-01 | Pythagoras Medical Ltd. | Controlled tissue ablation |
US9643008B2 (en) | 2012-11-09 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation |
US8923964B2 (en) | 2012-11-09 | 2014-12-30 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation |
US9452290B2 (en) | 2012-11-09 | 2016-09-27 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation |
WO2014126854A1 (en) | 2013-02-12 | 2014-08-21 | The Regents Of The University Of California | Circuit architecture for high channel count high-voltage neural stimulator |
US9643011B2 (en) | 2013-03-14 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation |
US9446241B2 (en) | 2013-03-15 | 2016-09-20 | Alfred E. Mann Foundation For Scientific Research | Current sensing multiple output current stimulators |
WO2014146019A2 (en) | 2013-03-15 | 2014-09-18 | Alfred E. Mann Foundation For Scientific Research | High voltage monitoring successive approximation analog to digital converter |
US9433779B2 (en) | 2013-05-03 | 2016-09-06 | Alfred E. Mann Foundation For Scientific Research | Multi-branch stimulation electrode for subcutaneous field stimulation |
US9221119B2 (en) | 2013-05-03 | 2015-12-29 | Alfred E. Mann Foundation For Scientific Research | High reliability wire welding for implantable devices |
US9308378B2 (en) | 2013-05-03 | 2016-04-12 | Alfred E. Mann Foundation For Scientific Research | Implant recharger handshaking system and method |
CA2919462C (en) | 2013-07-29 | 2018-03-06 | Alfred E. Mann Foundation For Scientific Research | Implant charging field control through radio link |
CN105263571B (en) | 2013-07-29 | 2017-06-09 | 艾尔弗雷德·E·曼科学研究基金会 | The E quasi-drivers of microprocessor control |
WO2015017474A2 (en) | 2013-07-29 | 2015-02-05 | Alfred E. Mann Foundation For Scientific Research | High efficiency magnetic link for implantable devices |
US9999773B2 (en) | 2013-10-30 | 2018-06-19 | Cyberonics, Inc. | Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters |
US9511228B2 (en) | 2014-01-14 | 2016-12-06 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation |
US9415224B2 (en) | 2014-04-25 | 2016-08-16 | Cyberonics, Inc. | Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction |
US9950169B2 (en) | 2014-04-25 | 2018-04-24 | Cyberonics, Inc. | Dynamic stimulation adjustment for identification of a neural fulcrum |
US9272143B2 (en) | 2014-05-07 | 2016-03-01 | Cyberonics, Inc. | Responsive neurostimulation for the treatment of chronic cardiac dysfunction |
US9409024B2 (en) | 2014-03-25 | 2016-08-09 | Cyberonics, Inc. | Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction |
US9713719B2 (en) | 2014-04-17 | 2017-07-25 | Cyberonics, Inc. | Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction |
EP3139853B1 (en) | 2014-05-07 | 2018-12-19 | Pythagoras Medical Ltd. | Controlled tissue ablation apparatus |
US9770599B2 (en) | 2014-08-12 | 2017-09-26 | Cyberonics, Inc. | Vagus nerve stimulation and subcutaneous defibrillation system |
US9737716B2 (en) | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
US9533153B2 (en) | 2014-08-12 | 2017-01-03 | Cyberonics, Inc. | Neurostimulation titration process |
JP6878269B2 (en) | 2014-08-15 | 2021-05-26 | アクソニクス モジュレーション テクノロジーズ インコーポレイテッド | Systems and Methods for Nerve Stimulation Electrode Configuration Based on Nerve Positioning |
US10682521B2 (en) | 2014-08-15 | 2020-06-16 | Axonics Modulation Technologies, Inc. | Attachment devices and associated methods of use with a nerve stimulation charging device |
EP3180071B1 (en) | 2014-08-15 | 2021-09-22 | Axonics, Inc. | External pulse generator device and associated system for trial nerve stimulation |
CA2958199C (en) | 2014-08-15 | 2023-03-07 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
CN112657054A (en) | 2014-08-15 | 2021-04-16 | 艾克索尼克斯调制技术股份有限公司 | Implantable lead attachment structures for neurostimulation to alleviate bladder dysfunction and other indications |
US10092762B2 (en) | 2014-08-15 | 2018-10-09 | Axonics Modulation Technologies, Inc. | Integrated electromyographic clinician programmer for use with an implantable neurostimulator |
US9504832B2 (en) | 2014-11-12 | 2016-11-29 | Cyberonics, Inc. | Neurostimulation titration process via adaptive parametric modification |
EP3242721B1 (en) | 2015-01-09 | 2019-09-18 | Axonics Modulation Technologies, Inc. | Attachment devices and associated methods of use with a nerve stimulation charging device |
CN107427683B (en) | 2015-01-09 | 2019-06-21 | 艾克索尼克斯调制技术股份有限公司 | For can plant the improvement antenna and application method of nerve stimulator |
EP3242712B1 (en) | 2015-01-09 | 2019-04-10 | Axonics Modulation Technologies, Inc. | Patient remote and associated methods of use with a nerve stimulation system |
US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
CN108271363B (en) | 2015-02-24 | 2022-08-09 | 伊莱拉股份有限公司 | System and method for achieving appetite regulation and/or improving dietary compliance using electrode patches |
US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
US20220062621A1 (en) | 2015-02-24 | 2022-03-03 | Elira, Inc. | Electrical Stimulation-Based Weight Management System |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
US11766568B2 (en) | 2015-07-10 | 2023-09-26 | Axonics, Inc. | Implantable nerve stimulator having internal electronics without ASIC and methods of use |
US10195423B2 (en) | 2016-01-19 | 2019-02-05 | Axonics Modulation Technologies, Inc. | Multichannel clip device and methods of use |
US9517338B1 (en) | 2016-01-19 | 2016-12-13 | Axonics Modulation Technologies, Inc. | Multichannel clip device and methods of use |
AU2017212551B2 (en) | 2016-01-29 | 2021-05-27 | Axonics, Inc. | Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator |
US10376704B2 (en) | 2016-02-12 | 2019-08-13 | Axonics Modulation Technologies, Inc. | External pulse generator device and associated methods for trial nerve stimulation |
US11678932B2 (en) | 2016-05-18 | 2023-06-20 | Symap Medical (Suzhou) Limited | Electrode catheter with incremental advancement |
US11110283B2 (en) | 2018-02-22 | 2021-09-07 | Axonics, Inc. | Neurostimulation leads for trial nerve stimulation and methods of use |
CA3092366C (en) | 2018-03-05 | 2022-12-06 | Neurostim Oab, Inc. | Non-invasive nerve stimulation |
US11642537B2 (en) | 2019-03-11 | 2023-05-09 | Axonics, Inc. | Charging device with off-center coil |
US11439829B2 (en) | 2019-05-24 | 2022-09-13 | Axonics, Inc. | Clinician programmer methods and systems for maintaining target operating temperatures |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3814080A (en) * | 1972-11-13 | 1974-06-04 | Becton Dickinson Co | Vessel cannulator and clamp for lymphangiography |
US3916875A (en) * | 1974-01-02 | 1975-11-04 | Herbert Toch | Lymph duct cannulation facilitator |
US4792330A (en) * | 1987-07-13 | 1988-12-20 | Lazarus Medical Innovations, Inc. | Combination catheter and duct clamp apparatus and method |
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5391143A (en) * | 1993-03-12 | 1995-02-21 | Kensey Nash Corporation | Method and system for effecting weight reduction of living beings |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5865744A (en) * | 1996-09-16 | 1999-02-02 | Lemelson; Jerome H. | Method and system for delivering therapeutic agents |
US6024704A (en) * | 1998-04-30 | 2000-02-15 | Medtronic, Inc | Implantable medical device for sensing absolute blood pressure and barometric pressure |
US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US6272370B1 (en) * | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
US6292695B1 (en) * | 1998-06-19 | 2001-09-18 | Wilton W. Webster, Jr. | Method and apparatus for transvascular treatment of tachycardia and fibrillation |
US20010041870A1 (en) * | 1999-03-09 | 2001-11-15 | Edward M. Gillis | Implantable device for access to a treatment site |
US20020029037A1 (en) * | 2000-09-06 | 2002-03-07 | Kim Young D. | Method and apparatus for percutaneous trans-endocardial reperfusion |
US6370417B1 (en) * | 1998-09-22 | 2002-04-09 | Siemens Akiengesellschaft | Method for positioning a catheter in a vessel, and device for implementing the method |
US6368274B1 (en) * | 1999-07-01 | 2002-04-09 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
US20020123674A1 (en) * | 2001-03-01 | 2002-09-05 | Gianni Plicchi | Process and implantable device for the intrapulmonary assessing of density dependant physical properties of the lung tissue |
US6475223B1 (en) * | 1997-08-29 | 2002-11-05 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling motion direction of a mechanically pushed catheter |
US20020188253A1 (en) * | 2001-06-07 | 2002-12-12 | Pharmaspec Corporation | Method and apparatus for drug delivery in veins |
US20030018247A1 (en) * | 2001-06-29 | 2003-01-23 | George Gonzalez | Process for testing and treating aberrant sensory afferents and motors efferents |
US20030036773A1 (en) * | 2001-08-03 | 2003-02-20 | Whitehurst Todd K. | Systems and methods for treatment of coronary artery disease |
US20030105506A1 (en) * | 2001-12-04 | 2003-06-05 | Cardiac Pacemakers, Inc. | Apparatus and method for stabilizing an implantable lead |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
US20030204185A1 (en) * | 2002-04-26 | 2003-10-30 | Sherman Marshall L. | System and method for monitoring use of disposable catheters |
US6741882B2 (en) * | 1999-12-02 | 2004-05-25 | Koninklijke Philips Electronics N.V. | MR device and MR method for localizing and/or visualizing a medical instrument provided with a passive magnet device |
US20040102804A1 (en) * | 1999-08-10 | 2004-05-27 | Chin Albert K. | Apparatus and methods for endoscopic surgical procedures |
US20040106953A1 (en) * | 2002-10-04 | 2004-06-03 | Yomtov Barry M. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
US6767686B2 (en) * | 2000-11-20 | 2004-07-27 | Sumitomo Chemical Company, Limited | Chemically amplifying type positive resist composition |
US20040158297A1 (en) * | 2001-06-29 | 2004-08-12 | George Gonzalez | Process for testing and treating motor and muscle function, sensory, autonomic, cognitive and neurologic disorders |
US20040193229A1 (en) * | 2002-05-17 | 2004-09-30 | Medtronic, Inc. | Gastric electrical stimulation for treatment of gastro-esophageal reflux disease |
US6804558B2 (en) * | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US20040210118A1 (en) * | 2003-04-18 | 2004-10-21 | Michel Letort | In situ detection of endoleak and endotension |
US20050043894A1 (en) * | 2003-08-22 | 2005-02-24 | Fernandez Dennis S. | Integrated biosensor and simulation system for diagnosis and therapy |
US20050043675A1 (en) * | 2003-08-21 | 2005-02-24 | Pastore Joseph M. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US20050049472A1 (en) * | 2003-08-29 | 2005-03-03 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
US20050075701A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for attenuating an immune response |
US20050075702A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US20050143787A1 (en) * | 2002-05-09 | 2005-06-30 | Boveja Birinder R. | Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator |
US20050143765A1 (en) * | 2002-09-04 | 2005-06-30 | Endoart Sa | Telemetrically controlled band for regulating functioning of a body organ or duct, and methods of making, implantation and use |
US20050149142A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation responsive to sensing feedback |
US20050149141A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation for altered perception to treat obesity |
US20050149014A1 (en) * | 2001-11-15 | 2005-07-07 | Quantumcor, Inc. | Cardiac valve leaflet attachment device and methods thereof |
US20050187584A1 (en) * | 2001-01-16 | 2005-08-25 | Stephen Denker | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
US20050240239A1 (en) * | 2005-06-29 | 2005-10-27 | Boveja Birinder R | Method and system for gastric ablation and gastric pacing to provide therapy for obesity, motility disorders, or to induce weight loss |
US20050240243A1 (en) * | 2004-02-25 | 2005-10-27 | Giancarlo Barolat | System and method for neurological stimulation of peripheral nerves to treat low back pain |
US20050267440A1 (en) * | 2004-06-01 | 2005-12-01 | Herman Stephen J | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
US20050288730A1 (en) * | 2002-04-08 | 2005-12-29 | Mark Deem | Methods and apparatus for renal neuromodulation |
US20060020333A1 (en) * | 2004-05-05 | 2006-01-26 | Lashinski Randall T | Method of in situ formation of translumenally deployable heart valve support |
US20070021731A1 (en) * | 1997-11-12 | 2007-01-25 | Garibaldi Jeffrey M | Method of and apparatus for navigating medical devices in body lumens |
US20070282382A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and device for lymphatic system monitoring |
US20070282386A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20070282390A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Amelioration of chronic pain by endolymphatic stimulation |
US20080009719A1 (en) * | 2006-06-06 | 2008-01-10 | Shuros Allan C | Method and apparatus for introducing endolymphatic instrumentation |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1074527A1 (en) | 1981-08-07 | 1984-02-23 | Киевский научно-исследовательский институт клинической и экспериментальной хирургии | Method of stimulation of lypmh drainage in external drainage of thoracic duct |
CH668191A5 (en) * | 1984-08-22 | 1988-12-15 | Sarcem Sa | REMOTE CONTROL CATHETER. |
US4909787A (en) * | 1986-08-14 | 1990-03-20 | Danforth John W | Controllable flexibility catheter with eccentric stiffener |
CA1327838C (en) * | 1988-06-13 | 1994-03-15 | Fred Zacouto | Implantable device to prevent blood clotting disorders |
US4957484A (en) | 1988-07-26 | 1990-09-18 | Automedix Sciences, Inc. | Lymph access catheters and methods of administration |
US5713926A (en) * | 1990-04-25 | 1998-02-03 | Cardiac Pacemakers, Inc. | Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode |
US5203348A (en) | 1990-06-06 | 1993-04-20 | Cardiac Pacemakers, Inc. | Subcutaneous defibrillation electrodes |
US5107834A (en) * | 1991-01-30 | 1992-04-28 | Cardiac Pacemakers, Inc. | Low energy multiple shock defibrillation/cardioversion discharge technique and electrode configuration |
US5405363A (en) * | 1991-03-15 | 1995-04-11 | Angelon Corporation | Implantable cardioverter defibrillator having a smaller displacement volume |
US5112303A (en) * | 1991-05-02 | 1992-05-12 | Pudenz-Schulte Medical Research Corporation | Tumor access device and method for delivering medication into a body cavity |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5203326A (en) * | 1991-12-18 | 1993-04-20 | Telectronics Pacing Systems, Inc. | Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy |
US5284153A (en) * | 1992-04-14 | 1994-02-08 | Brigham And Women's Hospital | Method for locating a nerve and for protecting nerves from injury during surgery |
US5333609A (en) | 1992-05-19 | 1994-08-02 | Minnesota Mining And Manufacturing Company | Catheter and probe-catheter assembly |
IT1260485B (en) | 1992-05-29 | 1996-04-09 | PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT | |
US5387231A (en) * | 1992-07-21 | 1995-02-07 | Sporer; Patsy | Electrotherapy method |
JP3273066B2 (en) | 1992-08-20 | 2002-04-08 | オリンパス光学工業株式会社 | Biological insertion tool |
SE9202662D0 (en) | 1992-09-16 | 1992-09-16 | Siemens Elema Ab | DEVICE FOR CREATING STIMULATION PULSES AND DEFIBRILLATION SHOCKS CREATED HEART DEFIBRILLATION SEQUENCES |
US5522853A (en) | 1992-10-27 | 1996-06-04 | Angeion Corporation | Method and apparatus for progressive recruitment of cardiac fibrillation |
US5496362A (en) | 1992-11-24 | 1996-03-05 | Cardiac Pacemakers, Inc. | Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation |
SE9203735D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | ELECTRIC SYSTEM FOR DEFIBRILLATOR |
US5792187A (en) | 1993-02-22 | 1998-08-11 | Angeion Corporation | Neuro-stimulation to control pain during cardioversion defibrillation |
US5697953A (en) | 1993-03-13 | 1997-12-16 | Angeion Corporation | Implantable cardioverter defibrillator having a smaller displacement volume |
KR0180315B1 (en) * | 1993-06-30 | 1999-03-20 | 알렌 제이. 스피겔 | Biphasic material |
SE9302358D0 (en) * | 1993-07-07 | 1993-07-07 | Siemens-Elema Ab | HJAERTSTIMULATOR |
US5468254A (en) | 1993-07-26 | 1995-11-21 | Cardiac Pacemakers, Inc. | Method and apparatus for defibrillation using a multiphasic truncated exponential waveform |
US5718718A (en) * | 1993-09-13 | 1998-02-17 | Angeion Corporation | Method and apparatus for polarity reversal of consecutive defibrillation countershocks having back biasing precharge pulses |
US5957956A (en) | 1994-06-21 | 1999-09-28 | Angeion Corp | Implantable cardioverter defibrillator having a smaller mass |
EP0688578B1 (en) | 1994-06-24 | 1999-11-10 | Pacesetter AB | Arrhythmia detector |
US5891084A (en) * | 1994-12-27 | 1999-04-06 | Lee; Vincent W. | Multiple chamber catheter delivery system |
US5662689A (en) | 1995-09-08 | 1997-09-02 | Medtronic, Inc. | Method and apparatus for alleviating cardioversion shock pain |
CA2246332C (en) | 1996-02-15 | 2009-04-14 | Biosense, Inc. | Catheter based surgery |
US5797967A (en) | 1996-09-27 | 1998-08-25 | Cardiac Pacemakers, Inc. | System and method to reduce defibrillation requirements |
US5817138A (en) * | 1996-11-27 | 1998-10-06 | Suzuki; James Y. | Multi-channel, interferential wave, micro current device and methods for treatment using micro current |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
CA2283128A1 (en) | 1997-03-14 | 1998-09-17 | Raymond E. Ideker | Method and apparatus for treating cardiac arrhythmia |
US6275730B1 (en) | 1997-03-14 | 2001-08-14 | Uab Research Foundation | Method and apparatus for treating cardiac arrythmia |
US5954752A (en) | 1997-04-30 | 1999-09-21 | Medtronic, Inc. | Cardioversion energy reduction system |
US5836976A (en) | 1997-04-30 | 1998-11-17 | Medtronic, Inc. | Cardioversion energy reduction system |
CA2331532A1 (en) * | 1998-05-08 | 1999-11-18 | Genetronics, Inc. | Electrically induced vessel vasodilation |
US6611715B1 (en) | 1998-10-26 | 2003-08-26 | Birinder R. Boveja | Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator |
US6366814B1 (en) * | 1998-10-26 | 2002-04-02 | Birinder R. Boveja | External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders |
US6134470A (en) | 1998-11-09 | 2000-10-17 | Medtronic, Inc. | Method and apparatus for treating a tachyarrhythmic patient |
US6115637A (en) | 1998-12-22 | 2000-09-05 | Universities Research Association, Inc. | Microcurrent therapeutic technique for treatment of radiation toxicity |
US6106477A (en) | 1998-12-28 | 2000-08-22 | Medtronic, Inc. | Chronically implantable blood vessel cuff with sensor |
US6077227A (en) | 1998-12-28 | 2000-06-20 | Medtronic, Inc. | Method for manufacture and implant of an implantable blood vessel cuff |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6629534B1 (en) | 1999-04-09 | 2003-10-07 | Evalve, Inc. | Methods and apparatus for cardiac valve repair |
US6542776B1 (en) | 1999-04-14 | 2003-04-01 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6895278B1 (en) * | 1999-04-14 | 2005-05-17 | Transneuronix, Inc. | Gastric stimulator apparatus and method for use |
US6606523B1 (en) | 1999-04-14 | 2003-08-12 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6684104B2 (en) | 1999-04-14 | 2004-01-27 | Transneuronix, Inc. | Gastric stimulator apparatus and method for installing |
US6692490B1 (en) * | 1999-05-18 | 2004-02-17 | Novasys Medical, Inc. | Treatment of urinary incontinence and other disorders by application of energy and drugs |
US6587719B1 (en) | 1999-07-01 | 2003-07-01 | Cyberonics, Inc. | Treatment of obesity by bilateral vagus nerve stimulation |
AU6953300A (en) * | 1999-07-07 | 2001-01-22 | Cardiac Pacemakers, Inc. | Endocardial electrode assembly having conductive fixation features |
US6408213B1 (en) | 1999-09-29 | 2002-06-18 | Cardiac Pacemakers, Inc. | Low profile, ventricular, transvenous, epicardial defibrillation lead |
US6272377B1 (en) | 1999-10-01 | 2001-08-07 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with arrhythmia prediction and prevention |
AU1790201A (en) * | 1999-11-24 | 2001-06-04 | Cardiac Pacemakers, Inc. | Method and apparatus for termination of cardiac tachyarrhythmias |
JP2001187035A (en) | 1999-12-28 | 2001-07-10 | Tanita Corp | Affected part recovery degree determination device |
US6826428B1 (en) | 2000-04-11 | 2004-11-30 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
DE10018334C1 (en) | 2000-04-13 | 2002-02-28 | Implex Hear Tech Ag | At least partially implantable system for the rehabilitation of a hearing impairment |
AU2001255713A1 (en) * | 2000-04-25 | 2001-11-07 | Harumi Naganuma | Noninvasive detection and activation of the lymphatic system in treating diseaseand alleviating pain |
DE10020846A1 (en) | 2000-04-28 | 2001-12-06 | Intelligent Implants Gmbh | Micro-contact structure for neuroprostheses for implantation on nerve tissue and method therefor |
US6584362B1 (en) | 2000-08-30 | 2003-06-24 | Cardiac Pacemakers, Inc. | Leads for pacing and/or sensing the heart from within the coronary veins |
US6950705B2 (en) * | 2000-09-18 | 2005-09-27 | Cameron Health, Inc. | Canister designs for implantable cardioverter-defibrillators |
US6647292B1 (en) | 2000-09-18 | 2003-11-11 | Cameron Health | Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer |
US6988003B2 (en) * | 2000-09-18 | 2006-01-17 | Cameron Health, Inc. | Implantable cardioverter-defibrillator having two spaced apart shocking electrodes on housing |
US7120495B2 (en) | 2000-09-18 | 2006-10-10 | Cameron Health, Inc. | Flexible subcutaneous implantable cardioverter-defibrillator |
US7043299B2 (en) * | 2000-09-18 | 2006-05-09 | Cameron Health, Inc. | Subcutaneous implantable cardioverter-defibrillator employing a telescoping lead |
US7069080B2 (en) | 2000-09-18 | 2006-06-27 | Cameron Health, Inc. | Active housing and subcutaneous electrode cardioversion/defibrillating system |
US6721597B1 (en) * | 2000-09-18 | 2004-04-13 | Cameron Health, Inc. | Subcutaneous only implantable cardioverter defibrillator and optional pacer |
US6952610B2 (en) | 2000-09-18 | 2005-10-04 | Cameron Health, Inc. | Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter- defibrillator |
US6788974B2 (en) | 2000-09-18 | 2004-09-07 | Cameron Health, Inc. | Radian curve shaped implantable cardioverter-defibrillator canister |
WO2002026317A1 (en) | 2000-09-26 | 2002-04-04 | Transneuronix, Inc. | Method and apparatus for treating obesity by electrical stimulation of the gastrointestinal tract using sensed activity |
US7198603B2 (en) * | 2003-04-14 | 2007-04-03 | Remon Medical Technologies, Inc. | Apparatus and methods using acoustic telemetry for intrabody communications |
US6615084B1 (en) | 2000-11-15 | 2003-09-02 | Transneuronix, Inc. | Process for electrostimulation treatment of morbid obesity |
US6950707B2 (en) * | 2000-11-21 | 2005-09-27 | Advanced Bionics Corporation | Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion |
US20020082658A1 (en) | 2000-11-22 | 2002-06-27 | Heinrich Stephen D. | Apparatus for detecting and treating ventricular arrhythmia |
US6609025B2 (en) | 2001-01-02 | 2003-08-19 | Cyberonics, Inc. | Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation |
MXPA03007008A (en) | 2001-02-06 | 2004-10-15 | Transvascular Inc | Methods and apparatus for guided transluminal interventions using vessel wall penetrating catheters and other apparatus. |
US6571125B2 (en) * | 2001-02-12 | 2003-05-27 | Medtronic, Inc. | Drug delivery device |
US7167751B1 (en) * | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
ITMI20010684A1 (en) * | 2001-03-30 | 2002-09-30 | Valerio Cigaina | DEVICE AND PROCEDURE FOR CHECKING THE ENTITY OF THE INTRA-ABDOMINAL FAT |
US7083593B2 (en) | 2001-04-18 | 2006-08-01 | Advanced Bionics Corporation | Programmable implantable pump with accessory reservoirs and multiple independent lumen catheter |
US6535764B2 (en) * | 2001-05-01 | 2003-03-18 | Intrapace, Inc. | Gastric treatment and diagnosis device and method |
US6735477B2 (en) * | 2001-07-09 | 2004-05-11 | Robert A. Levine | Internal monitoring system with detection of food intake |
US6678557B1 (en) * | 2001-08-20 | 2004-01-13 | Tvx Internet Services, Inc. | System and method for body fat management |
US6974448B2 (en) | 2001-08-30 | 2005-12-13 | Medtronic, Inc. | Method for convection enhanced delivery catheter to treat brain and other tumors |
US6893429B2 (en) * | 2001-08-30 | 2005-05-17 | Medtronic, Inc. | Convection enhanced delivery catheter to treat brain and other tumors |
US7778711B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6970741B1 (en) | 2001-09-18 | 2005-11-29 | Advanced Bionics Corporation | Monitoring, preventing, and treating rejection of transplanted organs |
US6934583B2 (en) * | 2001-10-22 | 2005-08-23 | Pacesetter, Inc. | Implantable lead and method for stimulating the vagus nerve |
US20030144708A1 (en) | 2002-01-29 | 2003-07-31 | Starkebaum Warren L. | Methods and apparatus for retarding stomach emptying for treatment of eating disorders |
US7689276B2 (en) * | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US7551964B2 (en) | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
US7123959B2 (en) | 2002-03-25 | 2006-10-17 | Cardiac Pacemakers, Inc. | Method and apparatus for preventing cardiac arrhythmias with endovascular stimulation |
US7191015B2 (en) * | 2002-04-11 | 2007-03-13 | Medtronic Vascular, Inc. | Devices and methods for transluminal or transthoracic interstitial electrode placement |
US20040015201A1 (en) * | 2002-04-22 | 2004-01-22 | Transneuronix, Inc. | Process for electrostimulation treatment of obesity |
US20050065553A1 (en) * | 2003-06-13 | 2005-03-24 | Omry Ben Ezra | Applications of vagal stimulation |
US7277761B2 (en) | 2002-06-12 | 2007-10-02 | Pacesetter, Inc. | Vagal stimulation for improving cardiac function in heart failure or CHF patients |
US7123961B1 (en) | 2002-06-13 | 2006-10-17 | Pacesetter, Inc. | Stimulation of autonomic nerves |
US7867193B2 (en) * | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US7769427B2 (en) | 2002-07-16 | 2010-08-03 | Magnetics, Inc. | Apparatus and method for catheter guidance control and imaging |
WO2004011085A1 (en) * | 2002-07-26 | 2004-02-05 | Transneuronix, Inc. | Improved process for electrostimulation treatment of morbid obesity |
JP2004065529A (en) | 2002-08-06 | 2004-03-04 | Takayuki Sato | Blood pressure controlling apparatus |
US6918873B1 (en) | 2002-09-19 | 2005-07-19 | Millar Instruments, Inc. | Inverted sensor module |
WO2004032791A2 (en) | 2002-09-20 | 2004-04-22 | Flowmedica, Inc. | Method and apparatus for selective material delivery via an intra-renal catheter |
US7986994B2 (en) | 2002-12-04 | 2011-07-26 | Medtronic, Inc. | Method and apparatus for detecting change in intrathoracic electrical impedance |
US7452334B2 (en) * | 2002-12-16 | 2008-11-18 | The Regents Of The University Of Michigan | Antenna stent device for wireless, intraluminal monitoring |
US8064994B2 (en) | 2003-01-14 | 2011-11-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Cervical vagal stimulation induced weight loss |
US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US7250041B2 (en) | 2003-03-12 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Retrograde pressure regulated infusion |
US7302294B2 (en) | 2003-04-11 | 2007-11-27 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac sensing and stimulation system employing blood sensor |
US7620454B2 (en) | 2003-05-19 | 2009-11-17 | Medtronic, Inc. | Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof |
EP1633434B1 (en) * | 2003-06-04 | 2014-11-19 | Synecor | Intravascular electrophysiological system |
US7617007B2 (en) | 2003-06-04 | 2009-11-10 | Synecor Llc | Method and apparatus for retaining medical implants within body vessels |
US7295877B2 (en) | 2003-07-31 | 2007-11-13 | Biosense Webster, Inc. | Encapsulated sensor with external antenna |
US20050038415A1 (en) | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
US20050070974A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Obesity and eating disorder stimulation treatment with neural block |
US7194301B2 (en) * | 2003-10-06 | 2007-03-20 | Transneuronic, Inc. | Method for screening and treating patients at risk of medical disorders |
US7200443B2 (en) * | 2003-10-07 | 2007-04-03 | John Faul | Transcutaneous electrical nerve stimulator for appetite control |
US7054690B2 (en) * | 2003-10-22 | 2006-05-30 | Intrapace, Inc. | Gastrointestinal stimulation device |
US7317941B2 (en) * | 2003-11-13 | 2008-01-08 | Medtronic, Inc. | Time syncrhonization of data |
WO2005051871A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
WO2005062823A2 (en) | 2003-12-19 | 2005-07-14 | Savacor, Inc. | Digital electrode for cardiac rhythm management |
US7203540B2 (en) * | 2003-12-22 | 2007-04-10 | Cardiac Pacemakers, Inc. | Method and system for setting cardiac resynchronization therapy parameters |
US7366572B2 (en) | 2004-03-16 | 2008-04-29 | Medtronic, Inc. | Controlling therapy based on sleep quality |
US20050222637A1 (en) | 2004-03-30 | 2005-10-06 | Transneuronix, Inc. | Tachygastrial electrical stimulation |
US20050222638A1 (en) | 2004-03-30 | 2005-10-06 | Steve Foley | Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders |
WO2005107461A2 (en) | 2004-04-07 | 2005-11-17 | The General Hospital Corporation | Modulating lymphatic function |
US20070244520A1 (en) | 2004-04-19 | 2007-10-18 | Searete Llc | Lumen-traveling biological interface device and method of use |
US8545414B2 (en) | 2004-04-30 | 2013-10-01 | St. Jude Medical, Cardiology Division, Inc. | Methods and devices for modulation of heart valve function |
GB0409769D0 (en) | 2004-04-30 | 2004-06-09 | Algotec Ltd | Electrical nerve stimulation device |
US7260431B2 (en) | 2004-05-20 | 2007-08-21 | Cardiac Pacemakers, Inc. | Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device |
US7803195B2 (en) | 2004-06-03 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
US7596413B2 (en) | 2004-06-08 | 2009-09-29 | Cardiac Pacemakers, Inc. | Coordinated therapy for disordered breathing including baroreflex modulation |
US20060074453A1 (en) * | 2004-10-04 | 2006-04-06 | Cvrx, Inc. | Baroreflex activation and cardiac resychronization for heart failure treatment |
AR047851A1 (en) | 2004-12-20 | 2006-03-01 | Giniger Alberto German | A NEW MARCAPASOS THAT RESTORES OR PRESERVES THE PHYSIOLOGICAL ELECTRIC DRIVING OF THE HEART AND A METHOD OF APPLICATION |
US8788044B2 (en) | 2005-01-21 | 2014-07-22 | Michael Sasha John | Systems and methods for tissue stimulation in medical treatment |
US7363082B2 (en) | 2005-03-24 | 2008-04-22 | Synecor Llc | Flexible hermetic enclosure for implantable medical devices |
US20060247601A1 (en) | 2005-04-19 | 2006-11-02 | Ellin Philip J | Method of improved drug delivery and for treatment of cellulitis |
WO2007016122A2 (en) * | 2005-07-27 | 2007-02-08 | Cook Incorporated | Implantable remodelable materials comprising magnetic material |
US20070027484A1 (en) * | 2005-07-28 | 2007-02-01 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a pancreatic disorder |
US7532935B2 (en) * | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US7774055B1 (en) | 2005-11-07 | 2010-08-10 | Pacesetter, Inc. | Left atrial pressure-based criteria for monitoring intrathoracic impedance |
WO2007067690A2 (en) | 2005-12-07 | 2007-06-14 | Drexel University | Detection of blood pressure and blood pressure waveform |
US7606622B2 (en) | 2006-01-24 | 2009-10-20 | Cardiac Pacemakers, Inc. | Method and device for detecting and treating depression |
EP1981584B1 (en) * | 2006-02-03 | 2015-05-13 | Interventional Autonomics Corporation | Intravascular device for neuromodulation |
WO2007109056A2 (en) | 2006-03-15 | 2007-09-27 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to diagnose and treat inflammatory diseases |
US7881797B2 (en) * | 2006-04-25 | 2011-02-01 | Valentx, Inc. | Methods and devices for gastrointestinal stimulation |
US7761166B2 (en) | 2006-04-28 | 2010-07-20 | Medtronic, Inc. | Electrical stimulation of iliohypogastric nerve to alleviate chronic pelvic pain |
US7809441B2 (en) | 2006-05-17 | 2010-10-05 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
US20070282376A1 (en) | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
US8905999B2 (en) * | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
US7664548B2 (en) * | 2006-10-06 | 2010-02-16 | Cardiac Pacemakers, Inc. | Distributed neuromodulation system for treatment of cardiovascular disease |
US20080294228A1 (en) | 2007-05-23 | 2008-11-27 | Cardiac Pacemakers | Method and device for controlled stimulation of lymphatic flow |
-
2006
- 2006-06-06 US US11/422,421 patent/US20070282376A1/en not_active Abandoned
-
2007
- 2007-05-10 EP EP07797400A patent/EP2032202A2/en not_active Withdrawn
- 2007-05-10 JP JP2009514448A patent/JP2009539492A/en not_active Withdrawn
- 2007-05-10 WO PCT/US2007/068617 patent/WO2007146517A2/en active Application Filing
-
2009
- 2009-10-22 US US12/604,233 patent/US8369943B2/en not_active Expired - Fee Related
Patent Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3814080A (en) * | 1972-11-13 | 1974-06-04 | Becton Dickinson Co | Vessel cannulator and clamp for lymphangiography |
US3916875A (en) * | 1974-01-02 | 1975-11-04 | Herbert Toch | Lymph duct cannulation facilitator |
US4792330A (en) * | 1987-07-13 | 1988-12-20 | Lazarus Medical Innovations, Inc. | Combination catheter and duct clamp apparatus and method |
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5391143A (en) * | 1993-03-12 | 1995-02-21 | Kensey Nash Corporation | Method and system for effecting weight reduction of living beings |
US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US5865744A (en) * | 1996-09-16 | 1999-02-02 | Lemelson; Jerome H. | Method and system for delivering therapeutic agents |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US6475223B1 (en) * | 1997-08-29 | 2002-11-05 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling motion direction of a mechanically pushed catheter |
US20070021731A1 (en) * | 1997-11-12 | 2007-01-25 | Garibaldi Jeffrey M | Method of and apparatus for navigating medical devices in body lumens |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
US6024704A (en) * | 1998-04-30 | 2000-02-15 | Medtronic, Inc | Implantable medical device for sensing absolute blood pressure and barometric pressure |
US6292695B1 (en) * | 1998-06-19 | 2001-09-18 | Wilton W. Webster, Jr. | Method and apparatus for transvascular treatment of tachycardia and fibrillation |
US6272370B1 (en) * | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
US6370417B1 (en) * | 1998-09-22 | 2002-04-09 | Siemens Akiengesellschaft | Method for positioning a catheter in a vessel, and device for implementing the method |
US20010041870A1 (en) * | 1999-03-09 | 2001-11-15 | Edward M. Gillis | Implantable device for access to a treatment site |
US6368274B1 (en) * | 1999-07-01 | 2002-04-09 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
US6804558B2 (en) * | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US20040102804A1 (en) * | 1999-08-10 | 2004-05-27 | Chin Albert K. | Apparatus and methods for endoscopic surgical procedures |
US6741882B2 (en) * | 1999-12-02 | 2004-05-25 | Koninklijke Philips Electronics N.V. | MR device and MR method for localizing and/or visualizing a medical instrument provided with a passive magnet device |
US20020029037A1 (en) * | 2000-09-06 | 2002-03-07 | Kim Young D. | Method and apparatus for percutaneous trans-endocardial reperfusion |
US6767686B2 (en) * | 2000-11-20 | 2004-07-27 | Sumitomo Chemical Company, Limited | Chemically amplifying type positive resist composition |
US20050187584A1 (en) * | 2001-01-16 | 2005-08-25 | Stephen Denker | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
US20020123674A1 (en) * | 2001-03-01 | 2002-09-05 | Gianni Plicchi | Process and implantable device for the intrapulmonary assessing of density dependant physical properties of the lung tissue |
US20020188253A1 (en) * | 2001-06-07 | 2002-12-12 | Pharmaspec Corporation | Method and apparatus for drug delivery in veins |
US20030018247A1 (en) * | 2001-06-29 | 2003-01-23 | George Gonzalez | Process for testing and treating aberrant sensory afferents and motors efferents |
US20040158297A1 (en) * | 2001-06-29 | 2004-08-12 | George Gonzalez | Process for testing and treating motor and muscle function, sensory, autonomic, cognitive and neurologic disorders |
US20030036773A1 (en) * | 2001-08-03 | 2003-02-20 | Whitehurst Todd K. | Systems and methods for treatment of coronary artery disease |
US20050149014A1 (en) * | 2001-11-15 | 2005-07-07 | Quantumcor, Inc. | Cardiac valve leaflet attachment device and methods thereof |
US20030105506A1 (en) * | 2001-12-04 | 2003-06-05 | Cardiac Pacemakers, Inc. | Apparatus and method for stabilizing an implantable lead |
US20050288730A1 (en) * | 2002-04-08 | 2005-12-29 | Mark Deem | Methods and apparatus for renal neuromodulation |
US20030204185A1 (en) * | 2002-04-26 | 2003-10-30 | Sherman Marshall L. | System and method for monitoring use of disposable catheters |
US20050143787A1 (en) * | 2002-05-09 | 2005-06-30 | Boveja Birinder R. | Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator |
US20040193229A1 (en) * | 2002-05-17 | 2004-09-30 | Medtronic, Inc. | Gastric electrical stimulation for treatment of gastro-esophageal reflux disease |
US20050143765A1 (en) * | 2002-09-04 | 2005-06-30 | Endoart Sa | Telemetrically controlled band for regulating functioning of a body organ or duct, and methods of making, implantation and use |
US20040106953A1 (en) * | 2002-10-04 | 2004-06-03 | Yomtov Barry M. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
US20040210118A1 (en) * | 2003-04-18 | 2004-10-21 | Michel Letort | In situ detection of endoleak and endotension |
US20050043675A1 (en) * | 2003-08-21 | 2005-02-24 | Pastore Joseph M. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US20050043894A1 (en) * | 2003-08-22 | 2005-02-24 | Fernandez Dennis S. | Integrated biosensor and simulation system for diagnosis and therapy |
US20050049472A1 (en) * | 2003-08-29 | 2005-03-03 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
US20050075701A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for attenuating an immune response |
US20050075702A1 (en) * | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US20050149141A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation for altered perception to treat obesity |
US20050149142A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation responsive to sensing feedback |
US20050240243A1 (en) * | 2004-02-25 | 2005-10-27 | Giancarlo Barolat | System and method for neurological stimulation of peripheral nerves to treat low back pain |
US20060020333A1 (en) * | 2004-05-05 | 2006-01-26 | Lashinski Randall T | Method of in situ formation of translumenally deployable heart valve support |
US20050267440A1 (en) * | 2004-06-01 | 2005-12-01 | Herman Stephen J | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
US20050240239A1 (en) * | 2005-06-29 | 2005-10-27 | Boveja Birinder R | Method and system for gastric ablation and gastric pacing to provide therapy for obesity, motility disorders, or to induce weight loss |
US20080009719A1 (en) * | 2006-06-06 | 2008-01-10 | Shuros Allan C | Method and apparatus for introducing endolymphatic instrumentation |
US20070282382A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and device for lymphatic system monitoring |
US20070282386A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20070282390A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Amelioration of chronic pain by endolymphatic stimulation |
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314630B2 (en) | 2002-04-08 | 2016-04-19 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients |
US8626300B2 (en) | 2002-04-08 | 2014-01-07 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for thermally-induced renal neuromodulation |
US11033328B2 (en) | 2002-04-08 | 2021-06-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US10850091B2 (en) | 2002-04-08 | 2020-12-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US10441356B2 (en) | 2002-04-08 | 2019-10-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation via neuromodulatory agents |
US10420606B2 (en) | 2002-04-08 | 2019-09-24 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US10376516B2 (en) | 2002-04-08 | 2019-08-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US10376311B2 (en) | 2002-04-08 | 2019-08-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravascularly-induced neuromodulation |
US10376312B2 (en) | 2002-04-08 | 2019-08-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for monopolar renal neuromodulation |
US10293190B2 (en) | 2002-04-08 | 2019-05-21 | Medtronic Ardian Luxembourg S.A.R.L. | Thermally-induced renal neuromodulation and associated systems and methods |
US10272246B2 (en) | 2002-04-08 | 2019-04-30 | Medtronic Adrian Luxembourg S.a.r.l | Methods for extravascular renal neuromodulation |
US8131372B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Renal nerve stimulation method for treatment of patients |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US8150518B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US10245429B2 (en) | 2002-04-08 | 2019-04-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US10179027B2 (en) | 2002-04-08 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable baskets for renal neuromodulation and associated systems and methods |
US8454594B2 (en) | 2002-04-08 | 2013-06-04 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8548600B2 (en) | 2002-04-08 | 2013-10-01 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatuses for renal neuromodulation and associated systems and methods |
US8551069B2 (en) | 2002-04-08 | 2013-10-08 | Medtronic Adrian Luxembourg S.a.r.l. | Methods and apparatus for treating contrast nephropathy |
US8620423B2 (en) | 2002-04-08 | 2013-12-31 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermal modulation of nerves contributing to renal function |
US9320561B2 (en) | 2002-04-08 | 2016-04-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for bilateral renal neuromodulation |
US8684998B2 (en) | 2002-04-08 | 2014-04-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for inhibiting renal nerve activity |
US8721637B2 (en) | 2002-04-08 | 2014-05-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons |
US8728137B2 (en) | 2002-04-08 | 2014-05-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US8728138B2 (en) | 2002-04-08 | 2014-05-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US8740896B2 (en) | 2002-04-08 | 2014-06-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons |
US8768470B2 (en) | 2002-04-08 | 2014-07-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monitoring renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US8771252B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8784463B2 (en) | 2002-04-08 | 2014-07-22 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US10179028B2 (en) | 2002-04-08 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating patients via renal neuromodulation |
US8818514B2 (en) | 2002-04-08 | 2014-08-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for intravascularly-induced neuromodulation |
US8845629B2 (en) | 2002-04-08 | 2014-09-30 | Medtronic Ardian Luxembourg S.A.R.L. | Ultrasound apparatuses for thermally-induced renal neuromodulation |
US8852163B2 (en) | 2002-04-08 | 2014-10-07 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods |
US8880186B2 (en) | 2002-04-08 | 2014-11-04 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients with chronic heart failure |
US10179235B2 (en) | 2002-04-08 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US10130792B2 (en) | 2002-04-08 | 2018-11-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs |
US8934978B2 (en) | 2002-04-08 | 2015-01-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US8948865B2 (en) | 2002-04-08 | 2015-02-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating heart arrhythmia |
US8958871B2 (en) | 2002-04-08 | 2015-02-17 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US10124195B2 (en) | 2002-04-08 | 2018-11-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for thermally-induced renal neuromodulation |
US8983595B2 (en) | 2002-04-08 | 2015-03-17 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients with chronic heart failure |
US8986294B2 (en) | 2002-04-08 | 2015-03-24 | Medtronic Ardian Luxembourg S.a.rl. | Apparatuses for thermally-induced renal neuromodulation |
US9023037B2 (en) | 2002-04-08 | 2015-05-05 | Medtronic Ardian Luxembourg S.A.R.L. | Balloon catheter apparatus for renal neuromodulation |
US10111707B2 (en) | 2002-04-08 | 2018-10-30 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of human patients |
US9072527B2 (en) | 2002-04-08 | 2015-07-07 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatuses and methods for renal neuromodulation |
US10105180B2 (en) | 2002-04-08 | 2018-10-23 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravascularly-induced neuromodulation |
US9125661B2 (en) | 2002-04-08 | 2015-09-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US9131978B2 (en) | 2002-04-08 | 2015-09-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for bilateral renal neuromodulation |
US9138281B2 (en) | 2002-04-08 | 2015-09-22 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets |
US9186213B2 (en) | 2002-04-08 | 2015-11-17 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US9186198B2 (en) | 2002-04-08 | 2015-11-17 | Medtronic Ardian Luxembourg S.A.R.L. | Ultrasound apparatuses for thermally-induced renal neuromodulation and associated systems and methods |
US10039596B2 (en) | 2002-04-08 | 2018-08-07 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus for renal neuromodulation via an intra-to-extravascular approach |
US9326817B2 (en) | 2002-04-08 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating heart arrhythmia |
US9265558B2 (en) | 2002-04-08 | 2016-02-23 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for bilateral renal neuromodulation |
US9289255B2 (en) | 2002-04-08 | 2016-03-22 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9463066B2 (en) | 2002-04-08 | 2016-10-11 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US10034708B2 (en) | 2002-04-08 | 2018-07-31 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for thermally-induced renal neuromodulation |
US9192715B2 (en) | 2002-04-08 | 2015-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal nerve blocking |
US9327122B2 (en) | 2002-04-08 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9364280B2 (en) | 2002-04-08 | 2016-06-14 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US9968611B2 (en) | 2002-04-08 | 2018-05-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for renal nerve blocking |
US9439726B2 (en) | 2002-04-08 | 2016-09-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9445867B1 (en) | 2002-04-08 | 2016-09-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation via catheters having expandable treatment members |
US9456869B2 (en) | 2002-04-08 | 2016-10-04 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for bilateral renal neuromodulation |
US9956410B2 (en) | 2002-04-08 | 2018-05-01 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US9468497B2 (en) | 2002-04-08 | 2016-10-18 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9474563B2 (en) | 2002-04-08 | 2016-10-25 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US9486270B2 (en) | 2002-04-08 | 2016-11-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9675413B2 (en) | 2002-04-08 | 2017-06-13 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for renal neuromodulation |
US9707035B2 (en) | 2002-04-08 | 2017-07-18 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9731132B2 (en) | 2002-04-08 | 2017-08-15 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for renal neuromodulation |
US9743983B2 (en) | 2002-04-08 | 2017-08-29 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients |
US9757192B2 (en) | 2002-04-08 | 2017-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients |
US9757193B2 (en) | 2002-04-08 | 2017-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Balloon catheter apparatus for renal neuromodulation |
US9814873B2 (en) | 2002-04-08 | 2017-11-14 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for bilateral renal neuromodulation |
US9827041B2 (en) | 2002-04-08 | 2017-11-28 | Medtronic Ardian Luxembourg S.A.R.L. | Balloon catheter apparatuses for renal denervation |
US9827040B2 (en) | 2002-04-08 | 2017-11-28 | Medtronic Adrian Luxembourg S.a.r.l. | Methods and apparatus for intravascularly-induced neuromodulation |
US9895195B2 (en) | 2002-04-08 | 2018-02-20 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9907611B2 (en) | 2002-04-08 | 2018-03-06 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation for treatment of patients |
US8433423B2 (en) | 2004-10-05 | 2013-04-30 | Ardian, Inc. | Methods for multi-vessel renal neuromodulation |
US8805545B2 (en) | 2004-10-05 | 2014-08-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for multi-vessel renal neuromodulation |
US9950161B2 (en) | 2004-10-05 | 2018-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for multi-vessel renal neuromodulation |
US9402992B2 (en) | 2004-10-05 | 2016-08-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for multi-vessel renal neuromodulation |
US10537734B2 (en) | 2004-10-05 | 2020-01-21 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for multi-vessel renal neuromodulation |
US9108040B2 (en) | 2004-10-05 | 2015-08-18 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for multi-vessel renal neuromodulation |
US12179014B2 (en) * | 2005-11-18 | 2024-12-31 | Zoll Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US7734341B2 (en) * | 2006-06-06 | 2010-06-08 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US7526337B2 (en) | 2006-06-06 | 2009-04-28 | Cardiac Pacemakers, Inc. | Method and device for lymphatic system monitoring |
US8369943B2 (en) | 2006-06-06 | 2013-02-05 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation via the lymphatic system |
US7894906B2 (en) | 2006-06-06 | 2011-02-22 | Cardiac Pacemakers, Inc. | Amelioration of chronic pain by endolymphatic stimulation |
US8126538B2 (en) | 2006-06-06 | 2012-02-28 | Cardiac Pacemakers, Inc. | Method and apparatus for introducing endolymphatic instrumentation |
US8897878B2 (en) | 2006-06-06 | 2014-11-25 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20070282382A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and device for lymphatic system monitoring |
US8905999B2 (en) | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
US9037244B2 (en) | 2007-02-13 | 2015-05-19 | Virender K. Sharma | Method and apparatus for electrical stimulation of the pancreatico-biliary system |
US20080195171A1 (en) * | 2007-02-13 | 2008-08-14 | Sharma Virender K | Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System |
US20080234556A1 (en) * | 2007-03-20 | 2008-09-25 | Cardiac Pacemakers, Inc. | Method and apparatus for sensing respiratory activities using sensor in lymphatic system |
US20100076279A1 (en) * | 2008-09-23 | 2010-03-25 | Shuros Allan C | Method and apparatus for organ specific inflammation monitoring |
US9186512B2 (en) | 2008-09-23 | 2015-11-17 | Cardiac Pacemakers, Inc. | Method and apparatus for organ specific inflammation monitoring |
US11517749B2 (en) | 2008-10-09 | 2022-12-06 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
US10376694B2 (en) | 2008-10-09 | 2019-08-13 | Virender K. Sharma | Method and apparatus for stimulating the vascular system |
US10603489B2 (en) | 2008-10-09 | 2020-03-31 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
US10537385B2 (en) | 2008-12-31 | 2020-01-21 | Medtronic Ardian Luxembourg S.A.R.L. | Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility |
US10561460B2 (en) | 2008-12-31 | 2020-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation systems and methods for treatment of sexual dysfunction |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
WO2010104700A1 (en) * | 2009-03-09 | 2010-09-16 | Cardiac Pacemakers, Inc. | Systems for autonomic nerve modulation comprising electrodes implantable in a lymphatic vessel |
US20100228310A1 (en) * | 2009-03-09 | 2010-09-09 | Shuros Allan C | Systems and methods for autonomic nerve modulation |
US20100256700A1 (en) * | 2009-04-07 | 2010-10-07 | Shuros Allan C | Method and apparatus for organ specific inflammation therapy |
US10179020B2 (en) | 2010-10-25 | 2019-01-15 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems and methods for evaluation and feedback of neuromodulation treatment |
US10874455B2 (en) | 2012-03-08 | 2020-12-29 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US11338140B2 (en) | 2012-03-08 | 2022-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring of neuromodulation using biomarkers |
US10080864B2 (en) | 2012-10-19 | 2018-09-25 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for catheter treatment devices and associated devices, systems, and methods |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
US11040199B2 (en) * | 2016-04-04 | 2021-06-22 | General Electric Company | Techniques for neuromodulation |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
CN111481830A (en) * | 2020-04-24 | 2020-08-04 | 上海交通大学 | Closed-loop electrical nerve stimulation system and method for setting parameters of closed-loop electrical nerve stimulation |
US12201836B2 (en) | 2021-06-08 | 2025-01-21 | General Electric Company | Techniques for neuromodulation |
WO2024239607A1 (en) * | 2023-05-19 | 2024-11-28 | 深圳先进技术研究院 | Lymph node regulation and control system and method |
Also Published As
Publication number | Publication date |
---|---|
WO2007146517A2 (en) | 2007-12-21 |
US20100042170A1 (en) | 2010-02-18 |
WO2007146517A3 (en) | 2008-05-02 |
EP2032202A2 (en) | 2009-03-11 |
JP2009539492A (en) | 2009-11-19 |
US8369943B2 (en) | 2013-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8369943B2 (en) | Method and apparatus for neural stimulation via the lymphatic system | |
US7734341B2 (en) | Method and apparatus for gastrointestinal stimulation via the lymphatic system | |
EP1919553B1 (en) | Safety control system for implantable neural stimulator | |
US7630760B2 (en) | Neural stimulation therapy system for atherosclerotic plaques | |
US7979141B2 (en) | Transvascular reshaping lead system | |
US8406881B2 (en) | Variable voltage compliance for current output generator | |
EP1812105B1 (en) | System and method for filtering neural stimulation | |
US7734348B2 (en) | System with left/right pulmonary artery electrodes | |
KR20020040801A (en) | Method to enhance cardiac capillary growth in heart failure patents | |
CA2515092A1 (en) | Brainstem and cerebellar modulation of cardiovascular response and disease | |
US9233247B2 (en) | Neuromodulation of renal nerve for treatment of hypertension | |
US20170049337A1 (en) | Implantable blood pressure monitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARDIAC PACEMAKERS, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHUROS, ALLAN C.;WESTLUND, RANDY;CAPARSO, ANTHONY V.;REEL/FRAME:018097/0583;SIGNING DATES FROM 20060714 TO 20060717 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |